Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
  • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
  • A01K67/027—New or modified breeds of vertebrates
  • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/12—Viral antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
  • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
  • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
  • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
  • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5005—Wall or coating material
  • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
  • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/51—Nanocapsules; Nanoparticles
  • A61K9/5107—Excipients; Inactive ingredients
  • A61K9/5123—Organic compounds, e.g. fats, sugars
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
  • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
  • C12N15/86—Viral vectors
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
  • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
  • A01K2267/00—Animals characterised by purpose
  • A01K2267/01—Animal expressing industrially exogenous proteins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
  • A61K2039/53—DNA (RNA) vaccination
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
  • C12N2770/00011—Details
  • C12N2770/36011—Togaviridae
  • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
  • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
  • C12N2770/00011—Details
  • C12N2770/36011—Togaviridae
  • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
  • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
  • C12N2770/00011—Details
  • C12N2770/36011—Togaviridae
  • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
  • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
  • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
  • C12N2770/00011—Details
  • C12N2770/36011—Togaviridae
  • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
  • C12N2770/36151—Methods of production or purification of viral material

Definitions

• the present disclosure relates to the field of molecular virology and immunology, and particularly relates to nucleic acid molecules encoding modified viral genomes and replicons (e.g., self-replicating RNAs), pharmaceutical compositions containing the same, and the use of such nucleic acid molecules and compositions for production of desired products in cell cultures or in a living body. Also provided are methods for inducing pharmacodynamic effects, e.g., eliciting an immune response, in a subject in need thereof, as well as methods for preventing and/or treating various health conditions.
• viral-based expression vectors have been deployed for expression of heterologous proteins in cultured recombinant cells.
• modified viral vectors for gene expression in host cells continues to expand.
• Recent advances in this regard include further development of techniques and systems for production of multisubunit protein complexes, and co-expression of protein-modifying enzymes to improve heterologous protein production.
• Other recent progresses regarding viral expression vector technologies include many advanced genome engineering applications for controlling gene expression, preparation of viral vectors, in vivo gene therapy applications, and creation of vaccine delivery vectors.
• replicons self-amplifying RNAs
• beneficial vaccine antigens or therapeutic agents For example, if a cell detects a replicon RNA (e.g, self-replicating RNA) expressing a beneficial protein and activates its innate immune defense mechanisms, the expression of the beneficial protein in such cell can be impacted and the efficacy of the replicon can be compromised.
• replicon RNA e.g, self-replicating RNA
• the present disclosure relates generally to the development of immuno- therapeutics, such as recombinant nucleic acids constructs and pharmaceutical compositions including the same for use in the prevention and management of various health conditions such as proliferative disorders and microbial infection.
• immuno- therapeutics such as recombinant nucleic acids constructs and pharmaceutical compositions including the same for use in the prevention and management of various health conditions such as proliferative disorders and microbial infection.
• some embodiments of the disclosure provide nucleic acid constructs containing sequences that encode a modified genome or replicon (e.g, self-replicating RNA) of the alphavirus Eastern Equine Encephalitis virus (EEEV) that is devoid at least a portion of the viral nucleic acid sequence encoding one or more structural proteins of the virus.
• EEEV alphavirus Eastern Equine Encephalitis virus
• nucleic acid constructs e.g ., vectors or srRNA molecules
• methods for producing a molecule of interest pharmaceutical compositions including one or more of the following: (a) a nucleic acid construct of the disclosure, (b) a polypeptide of the disclosure, (c) a recombinant cell of the disclosure.
• compositions and methods for inducing a pharmacodynamic effect e.g., eliciting an immune response in a subject in need thereof, and/or for the prevention and/or treatment of various health conditions, including proliferative disorders (e.g., cancers) and chronic infections.
• nucleic acid constructs including a nucleic acid sequence encoding a modified Eastern Equine Encephalitis virus (EEEV) genome or replicon RNA (e.g., self-replicating RNA), wherein the modified EEEV genome or replicon RNA is devoid of at least a portion of the nucleic acid sequence encoding one or more viral structural proteins.
• EEEV Eastern Equine Encephalitis virus
• Non-limiting exemplary embodiments of the nucleic acid constructs of the disclosure can include one or more of the following features.
• the modified viral genome or replicon RNA e.g., self-repli eating RNA
• the modified viral genome or replicon RNA includes no nucleic acid sequence encoding viral structural proteins.
• the nucleic acid molecules of the disclosure further include one or more expression cassettes, wherein each of the expression cassettes includes a promoter operably linked to a heterologous nucleic acid sequence.
• At least one of the expression cassettes includes a subgenomic ( sg ) promoter operably linked to a heterologous nucleic acid sequence.
• the sg promoter is a 26S subgenomic promoter.
• the nucleic acid molecules of the disclosure further include one or more untranslated regions (UTRs). In some embodiments, at least one of the UTRs is a heterologous UTR.
• At least one of expression cassettes includes a coding sequence for a gene of interest (GO I).
• the GOI encodes a polypeptide selected from the group consisting of a therapeutic polypeptide, a prophylactic polypeptide, a diagnostic polypeptide, a nutraceutical polypeptide, an industrial enzyme, and a reporter polypeptide.
• the GOI encodes a polypeptide selected from the group consisting of an antibody, an antigen, an immune modulator, an enzyme, a signaling protein, and a cytokine.
• the coding sequence of the GOI is optimized for expression at a level higher than the expression level of a reference coding sequence. In some embodiments, the coding sequence of the GOI is optimized for enhanced RNA stability.
• the nucleic acid construct of the disclosure is incorporated into a vector.
• the vector is a self-replicating RNA (srRNA) vector.
• the nucleic acid constructs of the disclosure include a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the nucleic acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, or SEQ ID NO: 18.
• recombinant cells including a nucleic acid construct as disclosed herein.
• the recombinant cell is a eukaryotic cell.
• the recombinant cell is an animal cell.
• the animal cell is a vertebrate animal cell or an invertebrate animal cell.
• the recombinant cell is a mammalian cell.
• the recombinant cell is selected from the group consisting of a monkey kidney CV1 cell transformed by SV40 (COS-7), a human embryonic kidney cell (e.g ., HEK 293 or HEK 293 cell), a baby hamster kidney cell (BHK), a mouse sertoli cell (e.g., TM4 cells), a monkey kidney cell (CV1), a human cervical carcinoma cell (HeLa), a canine kidney cell (MDCK), a buffalo rat liver cell (BRL 3A), a human lung cell (W138), a human liver cell (Hep G2), a mouse mammary tumor (MMT 060562), a TRI cell, a FS4 cell, a Chinese hamster ovary cell (CHO cell), an African green monkey kidney cell (Vero cell), a human A549 cell, a human cervix cell, a human CHME5 cell, a human PER.C6 cell, aNSO murine myelom
• the recombinant cell is an insect cell. In some embodiments, the recombinant cell is a mosquito cell.
• transgenic animals including a nucleic acid construct as described herein.
• the transgenic animal is a vertebrate animal or an invertebrate animal.
• the transgenic animal is a mammalian.
• the transgenic mammalian is a non-human mammalian.
• the transgenic animal is an insect.
• the transgenic insect is a transgenic mosquito.
• methods for producing a polypeptide of interest include (i) rearing a transgenic animal as disclosed herein; or (ii) culturing a recombinant cell including a nucleic acid construct as disclosed herein under conditions wherein the transgenic animal or recombinant cell produces the polypeptide encoded by the GOI.
• kits for producing a polypeptide of interest in a subject include administering to the subject a nucleic acid construct as disclosed herein.
• the subject is vertebrate animal or an invertebrate animal.
• the subject is an insect.
• the insect is a mosquito.
• the subject is a mammalian subject.
• the mammalian subject is a human subject.
• recombinant polypeptides produced by a method of the disclosure are provided herein.
• compositions including a pharmaceutically acceptable excipient and: a) a nucleic acid construct of the disclosure; b) a recombinant cell of the disclosure; and/or c) a recombinant polypeptide of the disclosure.
• compositions including a nucleic acid construct as disclosed herein and a pharmaceutically acceptable excipient are provided herein.
• the compositions include a recombinant polypeptide of as disclosed herein and a pharmaceutically acceptable excipient.
• the compositions are immunogenic compositions.
• the immunogenic compositions are formulated as a vaccine. In some embodiments, the immunogenic compositions are substantially non-immunogenic to a subject. In some embodiments, the pharmaceutical compositions are formulated as an adjuvant. In some embodiments, the pharmaceutical compositions are formulated for one or more of intranasal administration, transdermal administration, intraperitoneal administration, intramuscular administration, intranodal administration, intratumoral administration, intraarticular administration, intravenous administration, subcutaneous administration, intravaginal administration, intraocular, rectal, and oral administration.
• kits for inducing a pharmacodynamic effect in a subject and, in particular, methods for eliciting an immune response in a subject in need thereof include administering to the subject a composition including: a) a nucleic acid construct of the disclosure; b) a recombinant cell of the disclosure; c) a recombinant polypeptide of the disclosure; and/or d) a pharmaceutical composition of the disclosure.
• kits for preventing and/or treating a health condition in a subject in need thereof include prophylactically or therapeutically administering to the subject a composition including: a) a nucleic acid construct of the disclosure; b) a recombinant cell of the disclosure; c) a recombinant polypeptide of the disclosure; and/or d) a pharmaceutical composition of any one of the disclosure.
• Non-limiting exemplary embodiments of the methods of the disclosure can include one or more of the following features.
• the condition is a proliferative disorder or a microbial infection.
• the subject has or is suspected of having a condition associated with proliferative disorder or a microbial infection.
• the administered composition results in an increased production of interferon in the subject.
• the composition is administered to the subject individually as a single therapy (monotherapy) or as a first therapy in combination with at least one additional therapies.
• the at least one additional therapies is selected from the group consisting of chemotherapy, radiotherapy, immunotherapy, hormonal therapy, toxin therapy, targeted therapy, and surgery.
• kits for inducing a pharmacodynamic effect, for eliciting an immune response, for the prevention, and/or tor the treatment of a health condition or a microbial infection including: a) a nucleic acid construct of the disclosure; b) a recombinant cell of the disclosure; c) a recombinant polypeptide of the disclosure; and/or d) a pharmaceutical composition of the disclosure.
• FIG. 1 is graphical representation of a non-limiting example of a modified EEEV genome design in accordance with some embodiments of the disclosure, in which the nucleic acid sequence encoding viral structural proteins of the original virus have been completely deleted.
• the modified EEEV design described in this figure contains native 5’ UTR and 3’ UTR derived from the EEEV strain FL93-939, and further contains a heterologous gene of interest (GO I) placed under control of a 26S subgenomic promoter. Coding sequences for the non- structural proteins nsPl, nsP2, nsP3, and nsP4 are shown.
• FIGS. 2A-2B are graphical illustrations of non-limiting exemplary EEEV RNA replicon-based designs in accordance with some embodiments of the disclosure, in which the sequence encoding the modified EEEV genome from FL93-939 strain was incorporated into plasmid DNA vectors (FIG. 2A), which also included coding sequences for an exemplary gene of interest (GO I), e.g., hemagglutinin precursor (HA) of the influenza A virus H5N1 (FIG. 2B).
• GO I exemplary gene of interest
• HA hemagglutinin precursor
• FIGS. 3A-3B are contour plots of BHK-21 which have been transformed with EEEV RNA replicons (e.g., self-replicating RNAs).
• EEEV RNA replicons e.g., self-replicating RNAs.
• FIG. 3A an EEEV replicon RNA without a GOI was transformed by electroporation, and 20 hours following transformation, the cells were fixed and permeabilized and stained using a PE-conjugated anti-dsRNA mouse monoclonal antibody (J2, Scicons) to quantify the frequency of dsRNA+ cells by fluorescence flow cytometry.
• J2, Scicons PE-conjugated anti-dsRNA mouse monoclonal antibody
• an EEEV replicon RNA which includes the coding sequence for HA was similarly transformed into BHK-21 cells, and in addition to dsRNA detection, an APC- conjugated anti-HA mouse monoclonal antibody (2B7, Abeam) was used to detect transgene expression.
• an APC- conjugated anti-HA mouse monoclonal antibody (2B7, Abeam) was used to detect transgene expression.
• the positive staining of individual cells with both anti-dsRNA and anti-HA antibodies demonstrates that the modified EEEV designs described herein are viable synthetic replicons and able to undergo RNA replication and express transgenes.
• FIGS. 4A-4B schematically summarize the results of experiments demonstrating that modified EEEY vectors designed in accordance with some embodiments of the disclosure can be used to express two exemplary bioactive proteins: (i) interleukin-1 receptor antagonist protein (IL-1RA) and (ii) interleukin- 12 (IL-12).
• FIGS. 4A-4B are bar charts illustrating the quantification of secreted protein bioactivity from BHK-21 which were transformed with EEEV self-replicating RNAs (srRNAs).
• the srRNAs shown in FIGS. 4A-4B are EEEV srRNAs (RBI305, RBI306) each encoding two proteins IL-1RA and IL-12 in two different configurations.
• FIG. 4A shows the quantification of bioactive IL-1RA in the cell culture media at 24 and 48 hours following srRNA transformation.
• FIG. 4B shows the quantification of bioactive IL-12 in the cell culture media at 24 and 48 hours following srRNA transformation.
• FIGS. 5A-5B are bar charts illustrating in vivo immunogenicity of a panel of srRNAs encoding an exemplary viral antigen, which is an envelope glycoprotein G of a rabies virus (RABV-G).
• the panel included srRNAs derived from Venezuelan equine encephalitis virus (VEE.TC83), Chikungunya vims strains S27 (CHIK.S27) and DRDE-06 (CHIK.DRDE), Sindbis vims strains Girdwood (SIN GW), and AR87 (SIN.AR86), and Eastern encephalitis vims (EEE.FL93).
• FIG. 5A shows the quantification of antigen-specific splenic T cell responses evaluated by ELISpot after two immunizations.
• FIG. 5B shows anti-rabies neutralizing antibody titers from sera after two immunizations.
• FIGS. 6A-6C are bar charts showing in vivo immunogenicity of a panel of srRNAs encoding exemplary tumor-associated antigens for use as vaccine, e.g., for eliciting an immune response in a subject.
• the panel included srRNAs derived from Eastern encephalitis vims (EEE.FL93) and five other alphavimses: Venezuelan equine encephalitis vims (VEE.TC83), Chikungunya virus strains S27 (CHH .S27) and DRDE-06 (CHIK.URDE), Sindbis virus strains Girdwood (SIN.GW), and AR87 (SIN.AR86).
• Each srRNA includes sequences encoding for three polypeptides: sequence for estrogen receptor 1 (ESR1), human epidermal growth factor 2 (HER2), and human epidermal growth factor 2 (HER3).
• ESR1 estrogen receptor 1
• HER2 human epidermal growth factor 2
• HER3 human epidermal growth factor 2
• FIGS. 6A-6C show splenic T cell responses to these three antigens determined using ELISpot analysis in mice having received two immunizations, with statistical comparisons between each antigen tested.
• FIG. 7 is a bar chart illustrating in vivo expression levels of interleukin-12 (IL-12) from a panel of srRNAs encoding exemplary biotherapeutic protein (human IL-12).
• the panel included srRNAs derived from Venezuelan equine encephalitis virus (VEE.TC83), Chikungunya virus strains S27 (CHIK.S27) and DRDE-06 (CHIK.DRDE), Sindbis virus strains Girdwood (SIN.GW), and AR87 (SIN.AR86), and Eastern encephalitis virus (EEE.FL93).
• VEE.TC83 Venezuelan equine encephalitis virus
• CHIK.S27 Chikungunya virus strains S27
• DRDE-06 DRDE-06
• Sindbis virus strains Girdwood SIN.GW
• AR87 SIN.AR86
• EEEE.FL93 Eastern encephalitis virus
• FIG. 8 is a bar chart illustrating in vivo activity of IL-12 expressed from an EEEV srRNA vector encoding another exemplary biotherapeutic protein (mouse IL-12). Functionality of IL-12 was measured by assessing induction of IFNy, as a downstream pharmacodynamic marker. Sera from mice at Day 3 following administration of the srRNA showed detectable levels of IFNy.
• nucleic acid constructs such as, e.g. expression constructs and vectors, containing a modified genome or replicon RNA (e.g., self-replicating RNA) of an Eastern Equine Encephalitis virus (EEEV) in which at least some of its original viral sequence encoding structural proteins has been deleted.
• EEEV Eastern Equine Encephalitis virus
• viral-based expression vectors including one or more expression cassettes encoding heterologous polypeptide.
• recombinant cells that are genetically engineered to include one or more of the nucleic acid molecules disclosed herein. Biomaterials and recombinant products derived from such recombinant cells are also within the scope of the application.
• RNA viruses e.g., alphaviruses
• alphaviruses such as EEEV
• polypeptides such as therapeutic single chain antibodies may be most effective if expressed at high levels in vivo.
• high protein expression from a replicon RNA may increase overall yields of the antibody product.
• high level expression may induce the most robust immune response in vivo.
• Alphaviruses utilize motifs contained in their UTRs, structural regions, and non- structural regions to impact their replication in host cells. These regions also contain mechanism to evade host cell innate immunity.
• significant differences among alphavirus species have been reported.
• New World and Old World Alphaviruses have evolved different components to exploit stress granules, JAK-STAT signaling, FXR, and G3BP proteins within cells for assembly of viral replication complexes. Which part of the genome contains these components also varies between Alphaviruses.
• hypervariable domain (HVD) of nsP3 proteins have host-interactions that are specific for each alphavirus.
• HVD hypervariable domain
• EEEV nsP3 has been shown to interact with cellular FXR and G3BP protein families, DDX3, S100A4, IKKb, PGAM5, and cytoskeletal reorganization and vesicle trafficking proteins.
• EEEV has been considered the most pathogenic among alphaviruses and of the characterized EEEV strains, FL93-939 induces the highest IFN levels in mice.
• EEEV ability to interfere with stress granules, strain- dependent agnosticism to IFN, and other yet undescribed mechanisms that contribute to its strong pathogenicity suggest that EEEV would make an advantaged vector for expression of heterologous proteins for vaccine or biotherapeutic applications.
• the advantages that this vector confer has been up until now completely unexplored and unpredicted.
• the publicly available alphavirus genomic data does not always provide nucleotide sequences that are capable of direct replacement of the nucleic acid sequences encoding the structural proteins with a gene of interest (GOI) to result in self-replicating RNA and transgene-expressing replicons.
• GOI gene of interest
• simple replacement of EEEV structural proteins with heterologous genes using available, published sequences are not necessarily sufficient for generation of functional replicons.
• further engineering such as using heterologous 5’ and/or 3’ UTR sequences, would be required to create replicon systems suitable for use in vaccines and therapeutics.
• modified EEEV genomes or replicon RNAs e.g., self-replicating RNAs
• replicon RNAs e.g., self-replicating RNAs
• GO I heterologous genes of interest
• HA hemagglutinin precursor
• some EEEV-based srRNA constructs as described herein can be employed for expression of an antigen and formulated as a vaccine with a measured pharmacodynamic effect in vivo (see, e.g, FIG. 5 and FIG. 6).
• experimental data described in FIGS. 4A-4B demonstrate that EEEV-based srRNA vectors can be useful for expression of multiple proteins whose coding sequences are operably linked to one another within a single open reading frame (e.g, in a polycistronic ORF) and have bioactivity as measured by pharmacodynamic effect in vivo (see, e.g., FIG. 6).
• EEEV-based srRNA vectors of the present disclosure are also useful for expression of biotherapeutic proteins (see e.g, FIG. 7) with confirmed bioactivity in vivo (see e.g., FIG. 8). Taken together, these studies further demonstrate the use of EEEV srRNA in therapeutic and vaccine applications.
• a cell includes one or more cells, comprising mixtures thereof.
• a and/or B is used herein to include all of the following alternatives: “A”, “B”, “A or B”, and “A and B”.
• administration refers to the delivery of a bioactive composition or formulation by an administration route comprising, but not limited to, intranasal, transdermal, intravenous, intra-arterial, intramuscular, intranodal, intraperitoneal, subcutaneous, intramuscular, oral, intravaginal, and topical administration, or combinations thereof
• administration route comprising, but is not limited to, intranasal, transdermal, intravenous, intra-arterial, intramuscular, intranodal, intraperitoneal, subcutaneous, intramuscular, oral, intravaginal, and topical administration, or combinations thereof
• administration route comprising, but not limited to, intranasal, transdermal, intravenous, intra-arterial, intramuscular, intranodal, intraperitoneal, subcutaneous, intramuscular, oral, intravaginal, and topical administration, or combinations thereof
• the term includes, but is not limited to, administering by a medical professional and self-administering.
• cell refers not only to the particular subject cell, cell culture, or cell line but also to the progeny or potential progeny of such a cell, cell culture, or cell line, without regard to the number of transfers or passages in culture. It should be understood that not all progeny are exactly identical to the parental cell.
• progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein, so long as the progeny retain the same functionality as that of the original cell, cell culture, or cell line.
• a composition of the disclosure e.g., nucleic acid constructs (e.g., vectors or srRNA molecules), recombinant cells, recombinant polypeptides, and/or pharmaceutical compositions, generally refers to an amount sufficient for the composition to accomplish a stated purpose relative to the absence of the composition (e.g., achieve the effect for which it is administered, stimulate an immune response, prevent or treat a disease, or reduce one or more symptoms of a disease, disorder, infection, or health condition).
• an “effective amount” is an amount sufficient to contribute to the treatment, prevention, or reduction of a symptom or symptoms of a disease, which could also be referred to as a “therapeutically effective amount.”
• a “reduction” of a symptom means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s).
• the exact amount of a composition including a “therapeutically effective amount” will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed.,
• nucleic acid constructs refers to a recombinant molecule including one or more isolated nucleic acid sequences from heterologous sources.
• nucleic acid constructs can be chimeric nucleic acid molecules in which two or more nucleic acid sequences of different origin are assembled into a single nucleic acid molecule.
• representative nucleic acid constructs include any constructs that contain (1) nucleic acid sequences, including regulatory and coding sequences that are not found adjoined to one another in nature (e.g.
• nucleic acid constructs can include any recombinant nucleic acid molecules, linear or circular, single-stranded or double-stranded DNA or RNA nucleic acid molecules, derived from any source, such as a plasmid, cosmid, virus, autonomously replicating polynucleotide molecule, phage, capable of genomic integration or autonomous replication, comprising a nucleic acid molecule where one or more nucleic acid sequences have been operably linked.
• Constructs of the present disclosure can include the necessary elements to direct expression of a nucleic acid sequence of interest that is also contained in the construct.
• Such elements may include control elements such as a promoter that is operably linked to (so as to direct transcription of) the nucleic acid sequence of interest, and optionally includes a polyadenylation sequence.
• the nucleic acid construct may be incorporated within a vector.
• vector is used herein to refer to a nucleic acid molecule or sequence capable of transferring or transporting another nucleic acid molecule.
• vector encompasses both DNA-based vectors and RNA-based vectors.
• vector includes cloning vectors and expression vectors, as well as viral vectors and integrating vectors.
• An “expression vector” is a vector that includes a regulatory region, thereby capable of expressing DNA sequences and fragments in vitro , ex vivo , and/or in vivo.
• a vector may include sequences that direct autonomous replication in a cell such as, for example a plasmid (DNA-based vector) or a self-replicating RNA vector.
• a vector may include sequences sufficient to allow integration into host cell DNA.
• a vector may include DNA sequences that can be transcribed into RNA in vitro and/or in vivo.
• Useful vectors include, for example, plasmids (e.g., DNA plasmids or RNA plasmids), transposons, cosmids, bacterial artificial chromosomes, and viral vectors.
• the vector of the disclosure can be single-stranded vector (e.g., ssDNA or ssRNA). In some embodiments, the vector of the disclosure can be double-stranded vector (e.g, dsDNA or dsRNA). In some embodiments, a vector is a gene delivery vector. In some embodiments, a vector is used as a gene delivery vehicle to transfer a gene into a cell.
• the vector may include, for example, one or more selectable markers, one or more origins of replication, such as prokaryotic and eukaryotic origins, at least one multiple cloning site, and/or elements to facilitate stable integration of the construct into the genome of a cell.
• Two or more constructs can be incorporated within a single nucleic acid molecule, such as a single vector, or can be containing within two or more separate nucleic acid molecules, such as two or more separate vectors.
• An “expression construct” generally includes at least a control sequence operably linked to a nucleotide sequence of interest.
• promoters in operable connection with the nucleotide sequences to be expressed are provided in expression constructs for expression in a cell.
• compositions and methods for preparing and using constructs and cells are known to one skilled in the art.
• operably linked denotes a physical or functional linkage between two or more elements, e.g ., polypeptide sequences or polynucleotide sequences, which permits them to operate in their intended fashion.
• operably linked when used in context of the nucleic acid molecules described herein or the coding sequences and promoter sequences in a nucleic acid molecule means that the coding sequences and promoter sequences are in-frame and in proper spatial and distance away to permit the effects of the respective binding by transcription factors or RNA polymerase on transcription. It should be understood that operably linked elements may be contiguous or non-contiguous (e.g., linked to one another through a linker).
• operably linked refers to a physical linkage (e.g., directly or indirectly linked) between amino acid sequences (e.g. , different segments, portions, regions, or domains) to provide for a described activity of the constructs.
• Operably linked segments, portions, regions, and domains of the polypeptides or nucleic acid molecules disclosed herein may be contiguous or non-contiguous (e.g., linked to one another through a linker).
• portion refers to a fraction. With respect to a particular structure such as a polynucleotide sequence or an amino acid sequence or protein the term “portion” thereof may designate a continuous or a discontinuous fraction of said structure.
• a portion of an amino acid sequence comprises at least 1%, at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, and at least 90% of the amino acids of said amino acid sequence.
• said discontinuous fraction is composed of 2, 3, 4, 5, 6, 7, 8, or more parts of a structure (e.g, domains of a protein), each part being a continuous element of the structure.
• a discontinuous fraction of an amino acid sequence may be composed of 2, 3, 4, 5, 6, 7, 8, or more, for example not more than 4 parts of said amino acid sequence, wherein each part comprises at least 1, at least 2, at least 3, at least 4, at least 5 continuous amino acids, at least 10 continuous amino acids, at least 20 continuous amino acids, or at least 30 continuous amino acids of the amino acid sequence.
• percent identity refers to two or more sequences or subsequences that are the same or have a specified percentage of nucleotides or amino acids that are the same (e.g., about 60% sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection.
• sequences are then said to be “substantially identical.”
• This definition also refers to, or may be applied to, the complement of a sequence.
• This definition also includes sequences that have deletions and/or additions, as well as those that have substitutions.
• Sequence identity can be calculated using published techniques and widely available computer programs, such as the GCS program package (Devereux et al, Nucleic Acids Res. 12:387, 1984), BLASTP, BLASTN, FASTA (Atschul et al. , J Mol Biol 215:403, 1990). Sequence identity can be measured using sequence analysis software such as the Sequence Analysis Software Package of the Genetics Computer Group at the University of Wisconsin Biotechnology Center (1710 University Avenue, Madison, Wis. 53705), with the default parameters thereof.
• pharmaceutically acceptable excipient refers to any suitable substance that provides a pharmaceutically acceptable carrier, additive, or diluent for administration of a compound(s) of interest to a subject.
• pharmaceutically acceptable excipient can encompass substances referred to as pharmaceutically acceptable diluents, pharmaceutically acceptable additives, and pharmaceutically acceptable carriers.
• pharmaceutically acceptable carrier includes, but is not limited to, saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
• Supplementary active compounds e.g ., antibiotics and additional therapeutic agents
• recombinant when used with reference to a cell, a nucleic acid, a protein, or a vector, indicates that the cell, nucleic acid, protein or vector has been altered or produced through human intervention such as, for example, has been modified by or is the result of laboratory methods.
• recombinant proteins and nucleic acids include proteins and nucleic acids produced by laboratory methods.
• Recombinant proteins can include amino acid residues not found within the native (non-recombinant or wild-type) form of the protein or can be include amino acid residues that have been modified, e.g., labeled.
• the term can include any modifications to the peptide, protein, or nucleic acid sequence.
• Such modifications may include the following: any chemical modifications of the peptide, protein or nucleic acid sequence, including of one or more amino acids, deoxyribonucleotides, or ribonucleotides; addition, deletion, and/or substitution of one or more of amino acids in the peptide or protein; creation of a fusion protein, e.g, a fusion protein comprising an antibody fragment; and addition, deletion, and/or substitution of one or more of nucleic acids in the nucleic acid sequence.
• ’’recombinant when used in reference to a cell is not intended to include naturally-occurring cells but encompass cells that have been engineered/modified to include or express a polypeptide or nucleic acid that would not be present in the cell if it was not engineered/modified.
• replicon RNA refers to RNA which contains all of the genetic information required for directing its own amplification or self-replication within a permissive cell. Therefore, replicon RNA is sometimes also referred to as “self-amplifying RNA” (saRNA) or “self-replicating RNA” (srRNA).
• saRNA self-amplifying RNA
• srRNA self-replicating RNA
• the RNA molecule 1) encodes polymerase, replicase, or other proteins which may interact with viral or host cell-derived proteins, nucleic acids or ribonucleoproteins to catalyze the RNA amplification process; and 2) contain cA-acting RNA sequences required for replication and transcription of the subgenomic replicon-encoded RNA. These sequences may be bound during the process of replication to its self-encoded proteins, or non-self-encoded cell-derived proteins, nucleic acids or ribonucleoproteins, or complexes between any of these components.
• an alphavirus replicon RNA molecule e.g.
• srRNA or saRNA molecule generally contains the following ordered elements: 5' viral RNA sequence(s) required in cis for replication, sequences coding for biologically active alphavirus non-structural proteins (e.g., nsPl, nsP2, nsP3, and nsP4), promoter for the subgenomic RNA (sgRNA), 3 ' viral sequences required in cis for replication, and a polyadenylate tract (poly(A)).
• a subgenomic promoter (sg) that directs expression of a heterologous sequence can be included in the srRNA construct of the disclosure.
• replicon RNA e.g., srRNA or saRNA
• the replicon RNA does not contain the sequences of at least one of structural viral protein; sequences encoding structural genes can be substituted with heterologous sequences.
• the replicon RNA is to be packaged into a recombinant alphavirus particle, it can contain one or more sequences, so-called packaging signals, which serve to initiate interactions with alphavirus structural proteins that lead to particle formation.
• a “subject” or an “individual” includes animals, such as human ( e.g ., human individuals) and non-human animals.
• a “subject” or “individual” is a patient under the care of a physician.
• the subject can be a human patient or an individual who has, is at risk of having, or is suspected of having a health condition of interest (e.g., cancer or infection) and/or one or more symptoms of the health condition.
• the subject can also be an individual who is diagnosed with a risk of the health condition of interest at the time of diagnosis or later.
• non-human animals includes all vertebrates, e.g., mammals, e.g., rodents, e.g., mice, non-human primates, and other mammals, such as e.g., sheep, dogs, cows, chickens, and non-mammals, such as amphibians, reptiles, etc.
• mammals e.g., rodents, e.g., mice, non-human primates, and other mammals, such as e.g., sheep, dogs, cows, chickens, and non-mammals, such as amphibians, reptiles, etc.
• aspects and embodiments of the disclosure described herein include “comprising”, “consisting”, and “consisting essentially of aspects and embodiments.
• “comprising” is synonymous with “including”, “containing”, or “characterized by”, and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps.
• “consisting essentially of does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claimed composition or method.
• Eastern Equine Encephalitis virus is a mosquito-borne virus belonging to the genus Alphavinis which include a group of genetically, structurally, and serologically related viruses of the Togaviridae family.
• the alphavinis genus includes among others the Sindbis virus (SINV), the Semliki Forest virus (SFV), the Ross River virus (RRV), Venezuelan equine encephalitis virus (VEEV), and Eastern Equine Encephalitis virus (EEEV), which are all closely related and are able to infect various vertebrates such as mammalians, rodents, fish, avian species, and larger mammals such as humans and horses as well as invertebrates such as insects.
• Sindbis virus SINV
• SFV Semliki Forest virus
• RRV Ross River virus
• VEEV Venezuelan equine encephalitis virus
• EEEV Eastern Equine Encephalitis virus
• the EEEV has been widely studied and the life cycle, mode of replication, etc., of these viruses are well characterized. More information in this regard can be found in, e.g ., Corrin T. et al., Vector-Borne and Zoonotic Diseases, Vol. 21, No. 5, 2021.
• alphaviruses have been shown to replicate very efficiently in animal cells which makes them valuable as vectors for production of protein and nucleic acids in such cells. Transmission between species and individuals occurs mainly via mosquitoes making the alphaviruses a contributor to the collection of Arboviruses - or Arthropod-Borne Viruses.
• Each of these alphaviruses has a single stranded RNA genome of positive polarity enclosed in a nucleocapsid surrounded by an envelope containing viral spike proteins.
• Alphavirus particles are enveloped, tend to be spherical (although slightly pleomorphic), and have an isometric nucleocapsid.
• Alphavirus genome is single-stranded RNA of positive polarity of approximately 11-12 kb in length, comprising a 5’ cap, a 3’ poly-A tail, and two open reading frames with a first frame encoding the nonstructural proteins with enzymatic function and a second frame encoding the viral structural proteins (e.g., the capsid protein CP, El glycoprotein, E2 glycoprotein, E3 protein and 6K protein).
• EEEV possesses a single-stranded, positive-sense RNA genome of approximately 11.7 kb that is capped at the 5' end and polyadenylated at the 3' end.
• EEEV is transmitted by the bite of an infected mosquito and most spillover transmission occurs in low-lying areas with hardwood trees and swamps conducive of mosquito larvae development.
• EEEV can infect horses, causing fever, behavioral changes and other symptoms of encephalitis. Wild birds are the main reservoir for EEEV. However, infection is often deadly for horses.
• the 5' two-thirds of the alphavirus genome encodes a number of nonstructural proteins necessary for transcription and replication of viral RNA. These proteins are translated directly from the RNA and together with cellular proteins form the RNA-dependent RNA polymerase essential for viral genome replication and transcription of subgenomic RNA.
• Four nonstructural proteins (nsPl-4) are produced as a single polyprotein constitute the virus' replication machinery. The processing of the polyprotein occurs in a highly regulated manner, with cleavage at the P2/3 junction influencing RNA template use during genome replication.
• nsP3 creates a ring structure that encircles nsP2. These two proteins have an extensive interface. Mutations in nsP2 that produce noncytopathic viruses or a temperature sensitive phenotypes cluster at the P2/P3 interface region. P3 mutations opposite the location of the nsP2 noncytopathic mutations prevent efficient cleavage of P2/3. This in turn can affect RNA infectivity altering viral RNA production levels.
• the 3’ one-third of the genome comprises subgenomic RNA which serves as a template for translation of all the structural proteins required for forming viral particles: the core nucleocapsid protein C, and the envelope proteins P62 and El that associate as a heterodimer.
• the viral membrane-anchored surface glycoproteins are responsible for receptor recognition and entry into target cells through membrane fusion.
• the subgenomic RNA is transcribed from the p26S subgenomic promoter present at the 3' end of the RNA sequence encoding the nsP4 protein. The proteolytic maturation of P62 into E2 and E3 causes a change in the viral surface.
• glycoprotein "spikes” form an E1/E2 dimer or an E1/E2/E3 trimer, where E2 extends from the center to the vertices, El fills the space between the vertices, and E3, if present, is at the distal end of the spike.
• El Upon exposure of the virus to the acidity of the endosome, El dissociates from E2 to form an El homotrimer, which is necessary for the fusion step to drive the cellular and viral membranes together.
• the alphavirus glycoprotein El is a class II viral fusion protein, which is structurally different from the class I fusion proteins found in influenza virus and HIV.
• the E2 glycoprotein functions to interact with the nucleocapsid through its cytoplasmic domain, while its ectodomain is responsible for binding a cellular receptor. Most alphaviruses lose the peripheral protein E3, while in Semliki viruses it remains associated with the viral surface.
• Alphavirus replication has been reported to take place on membranous surfaces within the host cell.
• the 5' end of the genomic RNA is translated into a polyprotein (nsPl-4) with RNA polymerase activity that produces a negative strand complementary to the genomic RNA.
• the negative strand is used as a template for the production of two RNAs, respectively: (1) a positive genomic RNA corresponding to the genome of the secondary viruses producing, by translation, other nsP proteins and acting as a genome for the virus; and (2) subgenomic RNA encoding the structural proteins of the virus forming the infectious particles.
• the positive genomic RNA/subgenomic RNA ratio is regulated by proteolytic autocleavage of the polyprotein to nsPl, nsP2, nsP3 and nsP4.
• the viral gene expression takes place in two phases. In a first phase, there is main synthesis of positive genomic strands and of negative strands. During the second phase, the synthesis of subgenomic RNA is virtually exclusive, thus resulting in the production of large amount of structural protein.
• nucleic acid constructs a nucleic acid sequence encoding a modified viral genome or replicon RNA ⁇ e.g., self-replicating RNA), wherein the modified genome or replicon RNA is devoid of ( e.g . does not include) at least a portion of the nucleic acid sequence encoding one or more structural proteins of the corresponding unmodified viral genome or replicon RNA.
• Some embodiments of the disclosure provide a modified alphavirus genome or replicon RNA in which the coding sequence for non- structural proteins nsPl, nsP2, nsP3, and nsP4 is present, however at least a portion of or the entire sequence encoding one or more structural proteins is absent. Also provided are recombinant cells and cell cultures that have been engineered to include a nucleic acid construct as disclosed herein.
• a modified alphavirus genome can include deletion(s), substitution(s), and/or insertion(s) in one or more of the genomic regions of the parent alphavirus genome.
• Non-limiting exemplary embodiments of the nucleic acid constructs of the disclosure can include one or more of the following features.
• the nucleic acid constructs include a nucleic acid sequence encoding a modified EEEV genome or replicon RNA (e.g., self-replicating RNA), wherein the modified EEEV genome or replicon RNA is devoid of at least a portion of the nucleic acid sequence encoding one or more structural proteins of the unmodified EEEV genome or replicon RNA, e.g, the modified EEEV genome or replicon RNA does not include at least a portion of the coding sequence for one or more of the EEEV structural proteins CP, El, E2, E3, and 6K.
• a modified EEEV genome or replicon RNA e.g., self-replicating RNA
• the modified EEEV genome or replicon RNA is devoid of at least a portion of the nucleic acid sequence encoding one or more structural
• EEEV strains suitable for the compositions and methods of the disclosure include EEEV 792138, 783372, BeAn5122, BeAr300851, BeAr436087, C-49,
• the modified EEEV genome or replicon RNA is derived from EEEV strain FL93-939.
• Non-limiting exemplary embodiments of the nucleic acid constructs of the disclosure can include one or more of the following features.
• the modified viral genome or replicon RNA e.g., self-repli eating RNA
• the modified viral genome or replicon RNA is devoid of at least a portion of the nucleic acid sequence encoding one or more of the viral structural proteins CP, El, E2, E3, and 6K of the unmodified viral genome or replicon RNA.
• the modified viral genome or replicon RNA is devoid of a portion of or the entire sequence encoding CP.
• the modified viral genome or replicon RNA is devoid of a portion of or the entire sequence encoding El.
• the modified viral genome or replicon RNA is devoid of a portion of or the entire sequence encoding E2. In some embodiments, the modified viral genome or replicon RNA is devoid of a portion of or the entire sequence encoding E3. In some embodiments, the modified viral genome or replicon RNA is devoid of a portion of or the entire sequence encoding 6K. In some embodiments, the modified viral genome or replicon RNA is devoid of a portion of or the entire sequence encoding a combination of CP, El, E2, E3, and 6K.
• Some embodiments of the disclosure provide a modified EEEV genome or replicon RNA in which the coding sequence for non-structural proteins nsPl, nsP2, nsP3, and nsP4 of the unmodified EEEV genome or replicon RNA is present, however at least a portion of or the entire sequence encoding one or more structural proteins (e.g ., CP, El, E2, E3, and 6K) of the EEEV genome or replicon RNA is absent.
• structural proteins e.g ., CP, El, E2, E3, and 6K
• Some embodiments of the disclosure provide a modified EEEV genome or replicon RNA in which the coding sequence for non-structural proteins nsPl, nsP2, nsP3, and nsP4 of the unmodified EEEV genome or replicon RNA is present, however at least a portion of or the entire sequence encoding one or more structural proteins (e.g., CP, El, E2, E3, and 6K) of the EEEV genome or replicon RNA is absent.
• structural proteins e.g., CP, El, E2, E3, and 6K
• the modified viral genome or replicon RNA is devoid of a substantial portion of the nucleic acid sequence encoding one or more viral structural proteins.
• a substantial portion of a nucleic acid sequence encoding a viral structural polypeptide can include enough of the nucleic acid sequence encoding the viral structural polypeptide to afford putative identification of that polypeptide, either by manual evaluation of the sequence by one skilled in the art, or by computer-automated sequence comparison and identification using algorithms such as BLAST (see, for example, in “Basic Local Alignment Search Tool”; Altschul SF et ah, J. Mol. Biol.
• a substantial portion of a nucleotide sequence comprises enough of the sequence to afford specific identification and/or isolation of a nucleic acid fragment comprising the sequence.
• a substantial portion of a nucleic acid sequence can include at least about 20%, for example, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95% of the full length nucleic acid sequence.
• the present disclosure provides nucleic acid molecules and constructs which are devoid of partial or complete nucleic acid sequences encoding one or more viral structural proteins.
• the modified viral genome or replicon RNA (e.g ., self- replicating RNA) is devoid of the entire sequence encoding viral structural proteins, e.g. , the modified viral genome or replicon RNA includes no nucleic acid sequence encoding the structural proteins of the viral unmodified genome or replicon RNA.
• the nucleic acid constructs (e.g., vectors or srRNA constructs) of the disclosure generally have a length of at least about 2 kb.
• the nucleic acid constructs e.g., vectors or srRNAs
• the nucleic acid constructs can have a length of about 4 kb to about 20 kb, about 4 kb to about 18 kb, about 5 kb to about 16 kb, about 6 kb to about 14 kb, about 7 kb to about 12 kb, about 8 kb to about 16 kb, about 9 kb to about 14 kb, about 10 kb to about 18 kb, about 11 kb to about 16 kb, about 5 kb to about 18 kb, about 6 kb to about 20 kb, about 5 kb to about 10 kb, about 5 kb to about 8 kb, about 5 kb to about 7 kb, about 5 kb to about 6 kb, about 6 kb to about 12 kb, about 6 kb to about 11 kb, about 6 kb to about 10 kb, about 6 kb to about to about 6 kb to about 6 kb to about 6 kb
• the nucleic acid constructs can have a length of about 6 kb to about 14 kb. In some embodiments, the nucleic acid constructs (e.g., vectors or srRNAs) can have a length of about 6 kb to about 16 kb.
• the nucleic acid constructs of the disclosure further include one or more expression cassettes.
• the nucleic acid constructs disclosed herein can generally include any number of expression cassettes.
• the nucleic acid constructs disclosed herein can include at least two, at least three, at least four, at least five, or at least six expression cassettes.
• expression cassette refers to a construct of genetic material that contains coding sequences and enough regulatory information to direct proper transcription and/or translation of the coding sequences in a cell, in vivo and/or ex vivo. The expression cassette may be inserted into a vector for targeting to a desired host cell and/or into a subject.
• the term expression cassette may be used interchangeably with the term “expression construct.”
• expression cassette refers to a nucleic acid construct that includes a gene encoding a protein or functional RNA operably linked to regulatory elements such as, for example, a promoter and/or a termination signal, and optionally, any or a combination of other nucleic acid sequences that affect the transcription or translation of the gene.
• At least one of the expression cassettes includes a promoter operably linked to a heterologous nucleic acid sequence.
• the nucleic acid constructs as provided herein can find use, for example, as an expression vector that, when including a regulatory element (e.g, a promoter) operably linked to a heterologous nucleic acid sequence, can affect expression of the heterologous nucleic acid sequence.
• at least one of the expression cassettes includes a subgenomic (sg) promoter operably linked to a heterologous nucleic acid sequence.
• the sg promoter is a 26S subgenomic promoter.
• the nucleic acid molecules of the disclosure further include one or more untranslated regions (UTRs). In some embodiments, at least one of the UTRs is a heterologous UTR.
• At least one of expression cassettes includes a coding sequence for a gene of interest (GO I).
• the coding sequence of the GOI is redesigned and/or optimized for a desired property, such as increased stability, potency, and expression (e.g, translation efficiency), which in turns can maximize the impact of producing, delivering, and administering biotherapeutic.
• the coding sequence of the GOI is optimized for expression at a level higher than the expression level of a reference coding sequence.
• nucleic acid constructs of the present disclosure may also have any base sequence that has been changed from any polynucleotide sequence disclosed herein by substitution in accordance with degeneracy of the genetic code. References describing codon usage are readily publicly available.
• polynucleotide sequence variants can be produced for a variety of reasons, e.g., to optimize expression for a particular host (e.g., changing codon usage in the alphavirus mRNA to those preferred by other organisms such as human, non-human primates, hamster, mice, or monkey).
• the coding sequence of the GOI is optimized for expression at a level higher than the expression level of a reference coding sequence, such as, for example, a coding sequence that has not been codon-optimized in a target host cell through the use of codons optimized for expression.
• the codon-optimized sequence of the GOI results in an increased expression level by at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 100% compared to a reference coding sequence that has not been codon-optimized.
• the codon- optimized sequence of the GOI results in an increased expression level by at least 2-fold, at least 3-fold, at least 4-fold, or at least 5-fold compared to a reference coding sequence that has not been codon-optimized.
• the techniques for the construction of synthetic nucleic acid sequences encoding GOI using preferred codons optimal for host cell expression may be determined by computational methods analyzing the commonality of codon usage for encoding native proteins of the host cell genome and their relative abundance by techniques well known in the art.
• the codon usage database http://www.kazusa.or.jp/codon) may be used for generation of codon optimized sequences in mammalian cell environments.
• the coding sequence of the GOI is optimized for enhanced RNA stability and/or expression.
• the stability of RNA generally relates to the “half-life” of RNA.
• “Half-life” relates to the period of time which is needed to eliminate half of the activity, amount, or number of molecules.
• the half-life of an RNA is indicative for the stability of said RNA.
• the half-life of RNA may influence the “duration of expression” of the RNA. Additional information regarding principles, strategies, and methods for use in enhancing RNA stability can be found at, for example, Leppek K. et al., Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics. bioRxiv. (Preprint). Mar 30, 2021. doi: 10.1101/2021.03.29.437587.
• the polypeptide encoded by a GOI can generally be any polypeptide, and can be, for example a therapeutic polypeptide, a prophylactic polypeptide, a diagnostic polypeptide, a nutraceutical polypeptide, an industrial enzyme, and a reporter polypeptide.
• the GOI encodes a polypeptide that can be an antibody, an antigen, an immune modulator, an enzyme, a signaling protein, or a cytokine.
• the GOI can encode microbial proteins, viral proteins, bacterial proteins, fungal proteins, mammalian proteins, and combinations of any thereof.
• the GOI encodes a hemagglutinin precursor (HA) of the influenza A virus H5N1.
• HA hemagglutinin precursor
• Non-limiting examples of GOI include interleukins and interacting proteins, including: G-CSF, GM-CSF, IL-1, IL-10, IL- 10- like, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, EL-17, IL-18, IL-18BP, IL-l-like, IL-1RA, IL-la, IL-Ib, IL-2, IL-20, IL-3, IL-4, IL-5, IL-6, IL-6-like, IL-7, IL-9, IL-21, IL-22, IL-33, IL-37, IL- 38, LIF, and OSM.
• Additional suitable GOIs include, but are not limited to, interferons (e.g ., IFN-a, IFN-b, IFN-g), TNFs (e.g., CD154, LT-b, TNF-a, TNF-b, 4-1BBL, APRIL, CD70, CD153, CD178, GITRL, LIGHT, OX40L, TALL-1, TRAIL, TWEAK, and TRANCE), TGF-b (e.g, TGF-bI, T ⁇ R-b2, and T ⁇ R-b3), hematopoietins (e.g, Epo, Tpo, Flt-3L, SCF, M-CSF, MSP), chemokines and their receptors (e.g., XCL1, XCL2, CCL1, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL
• compositions and methods of the disclosure include, but are not limited to, immunostimulatory gene products (e.g., CD27/CD70, CD40, CD40L, B7.1, BTLA, MAVS, 0X40, OX40L, RIG-I, and STING), drug resistant mutants/variants of genes, such as ABCBl, ABCCl, ABCG2, AKT1, ALK, BAFF, BCR-ABL, BRAF, CCND1, cMET, EGFR, ERBB2, ERBB3, ERK2, ESR1, GRB2, KRAS, MDR1, MRP1, NTRKl, PDC4, P-gp, PI3K, PTEN, RET, ROS1, RSK1, RSK2, SHIP, and STK11. Also suitable for the compositions and methods of the disclosure includes
• the GOI can encode an antibody or antibody variant (e.g . single chain Fv, bi-specifics, camelids, Fab, and HCAb).
• the antibody targets surface molecules associated or upregulated with cancers, or surface molecules associated with infectious disease.
• the antibody targets surface molecules having immunostimulatory function, or having immunosuppressive function.
• the GOI can encode an enzyme whose deficiency or mutation is associated with diseases or health conditions, such as, for example, agalsidase beta, agalsidase alfa, imiglucerase, taliglucerase alfa, velaglucerase alfa, alglucerase, sebelipase alpha, laronidase, idursulfase, elosulfase alpha, galsulfase, alglucosidase alpha, and CTFR.
• diseases or health conditions such as, for example, agalsidase beta, agalsidase alfa, imiglucerase, taliglucerase alfa, velaglucerase alfa, alglucerase, sebelipase alpha, laronidase, idursulfase, elosulfase alpha, galsulfase, alglucosidase alpha, and CT
• the GOI can encode a polypeptide selected from antigen molecules, biotherapeutic molecules, or combinations of any thereof.
• the GOI can encode a polypeptide selected from tumor-associated antigens, tumor-specific antigens, neoantigens, and combinations of any thereof.
• the GOI can encode a polypeptide selected from estrogen receptors, intracellular signal transducer enzymes, and human epidermal growth receptors.
• the GOI can encode a biotherapeutic polypeptide selected from immunomodulators, modulators of angiogenesis, modulators of extracellular matrix, modulators of metabolism, neurological modulators, and combinations of any thereof.
• the GOI can encode a cytokine selected from chemokines, interferons, interleukins, lymphokines, and tumor necrosis factors.
• the GOI can encode an interleukins selected from IL-la, IL-Ib, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-15, IL-15, IL-17, IL-23, IL-27, IL-35, IFNy and subunits of any thereof.
• the GOI can encode a biotherapeutic polypeptide is selected from IL-12A, IL-12B, IL-1RA, and combinations of any thereof.
• the nucleic acid construct of the disclosure may be incorporated within a vector.
• the vector of the disclosure may be single- stranded vector, e.g., ssDNA vector or ssRNA vector.
• the vector of the disclosure can be double-stranded vector, e.g., dsDNA vector or dsRNA vector.
• the vector of the disclosure can be a plasmid.
• the vector of the disclosure can be produced using recombinant DNA technology, e.g., polymerase chain reaction (PCR) amplification, rolling circle amplification (RCA), molecular cloning, etc., or chemical synthesis.
• the vector of the disclosure can be a fully synthetic vector, e.g., fully synthetic ssDNA vector. In some embodiments, the vector of the disclosure can be a fully synthetic dsDNA vector. In some embodiments, the vector of the disclosure can be a product of a PCR reaction. In some embodiments, the vector of the disclosure can be a product of an RCA reaction. In some embodiments, a vector can be a gene delivery vector. In some embodiments, a vector can be used as a gene delivery vehicle to transfer a gene into a cell.
• the nucleic acid constructs of the disclosure include a nucleic acid sequence encoding a modified EEEV having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to a nucleic acid sequence of SEQ ID NO: 1.
• the nucleic acid constructs of the disclosure include a nucleic acid sequence encoding a modified EEEV having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to a nucleic acid sequence of SEQ ID NO: 2.
• the nucleic acid constructs of the disclosure include a nucleic acid sequence encoding a modified EEEV having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to a nucleic acid sequence of SEQ ID NO: 15.
• the nucleic acid constructs of the disclosure include a nucleic acid sequence encoding a modified EEEV having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to a nucleic acid sequence of SEQ ID NO: 16.
• the nucleic acid constructs of the disclosure include a nucleic acid sequence encoding a modified EEEV having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to a nucleic acid sequence of SEQ ID NO: 17.
• the nucleic acid constructs of the disclosure include a nucleic acid sequence encoding a modified EEEV having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to a nucleic acid sequence of SEQ ID NO: 18.
• Nucleic acid sequences having a high degree of sequence identity e.g, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%
• sequences identified herein e.g., SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, or SEQ ID NO: 18
• sequences identified herein e.g., SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, or SEQ ID NO: 18
• the nucleic acid molecules are recombinant nucleic acid molecules.
• the term recombinant nucleic acid molecule means any nucleic acid molecule (e.g . DNA, RNA), that is, or results, however indirect, from human manipulation.
• a cDNA is a recombinant DNA molecule, as is any nucleic acid molecule that has been generated by in vitro polymerase reaction(s), or to which linkers have been attached, or that has been integrated into a vector, such as a cloning vector or expression vector.
• a recombinant nucleic acid molecule 1) has been synthesized or modified in vitro, for example, using chemical or enzymatic techniques (for example, by use of chemical nucleic acid synthesis, or by use of enzymes for the replication, polymerization, exonucleolytic digestion, endonucleolytic digestion, ligation, reverse transcription, transcription, base modification (including, e.g., methylation), or recombination (including homologous and site-specific recombination) of nucleic acid molecules; 2) includes conjoined nucleotide sequences that are not conjoined in nature; 3) has been engineered using molecular cloning techniques such that it lacks one or more nucleotides with respect to the naturally occurring nucleotide sequence; and/or 4) has been manipulated using molecular cloning techniques such that it has one or more sequence changes or rearrangements with respect to the naturally occurring nucleotide sequence.
• chemical or enzymatic techniques for example, by
• nucleic acid molecules disclosed herein are produced using recombinant DNA technology (e.g., polymerase chain reaction (PCR) amplification, cloning, etc.) or chemical synthesis.
• Nucleic acid molecules as disclosed herein include natural nucleic acid molecules and homologs thereof, including, but not limited to, natural allelic variants and modified nucleic acid molecules in which one or more nucleotide residues have been inserted, deleted, and/or substituted, in such a manner that such modifications provide the desired property in effecting a biological activity as described herein.
• a nucleic acid molecule including a variant of a naturally-occurring nucleic acid sequence, can be produced using a number of methods known to those skilled in the art (see, for example, Sambrook et al, In: Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1989)).
• nucleic acid molecule can be modified with respect to a naturally-occurring sequence from which it is derived using a variety of techniques including, but not limited to, classic mutagenesis techniques and recombinant DNA techniques, such as but not limited to site-directed mutagenesis, chemical treatment of a nucleic acid molecule to induce mutations, restriction enzyme cleavage of a nucleic acid fragment, ligation of nucleic acid fragments, PCR amplification and/or mutagenesis of selected regions of a nucleic acid sequence, recombinational cloning, and chemical synthesis, including chemical synthesis of oligonucleotide mixtures and ligation of mixture groups to "build" a mixture of nucleic acid molecules, and combinations thereof
• Nucleic acid molecule homologs can be selected from a mixture of modified nucleic acid molecules by screening for the function of the protein or the replicon (e.g., srRNA) encoded by the nucleic acid molecule and/or by
• one aspect of the present disclosure relates to recombinant cells that have been engineered to include a nucleic acid construct as described herein and/or include (e.g., express) a nucleic acid construct as described herein.
• a nucleic acid construct e.g., vector or srRNA
• the nucleic acid constructs of the present disclosure can be introduced into a host cell to produce a recombinant cell containing the nucleic acid molecule.
• prokaryotic or eukaryotic cells that contain a nucleic acid construct encoding a modified EEEV genome as described herein are also features of the disclosure.
• some embodiments disclosed herein relate to methods of transforming a cell which includes introducing into a host cell, such as an animal cell, a nucleic acid construct as provided herein, and then selecting or screening for a transformed cell.
• nucleic acid constructs of the disclosure into cells can be achieved by methods known to those skilled in the art such as, for example, viral infection, transfection, conjugation, protoplast fusion, lipofection, electroporation, nucleofection, calcium phosphate precipitation, polyethyleneimine (PEI)- mediated transfection, DEAE-dextran mediated transfection, liposome-mediated transfection, particle gun technology, direct micro-injection, nanoparticle-mediated nucleic acid delivery, and the like.
• PKI polyethyleneimine
• DEAE-dextran mediated transfection DEAE-dextran mediated transfection
• liposome-mediated transfection liposome-mediated transfection
• particle gun technology direct micro-injection, nanoparticle-mediated nucleic acid delivery, and the like.
• some embodiments of the disclosure relate to recombinant cells, for example, recombinant eukaryotic cells, e.g., animal cells that include a nucleic acid construct described herein.
• the nucleic acid construct can be stably integrated in the host genome, or can be episomally replicating, or present in the recombinant host cell as a mini-circle expression vector for a stable or transient expression. Accordingly, in some embodiments of the disclosure, the nucleic acid construct is maintained and replicated in the recombinant host cell as an episomal unit. In some embodiments, the nucleic acid construct is stably integrated into the genome of the recombinant cell. Stable integration can be completed using classical random genomic recombination techniques or with more precise genome editing techniques such as using guide RNA directed CRISPR/Cas9 or TALEN genome editing. In some embodiments, the nucleic acid construct present in the recombinant host cell as a mini-circle expression vector for a stable or transient expression.
• Host cells can be either untransformed cells or cells that have already been transfected with at least one nucleic acid molecule. Accordingly, in some embodiments, host cells can be genetically engineered (e.g., transduced or transformed or transfected) with at least one nucleic acid molecule.
• Suitable host cells for cloning or expression of the protein of interest as described herein include prokaryotic or eukaryotic cells described herein.
• the recombinant cell is a prokaryotic cell, such as the bacterium E. coli, or a eukaryotic cell, such as an insect cell (e.g, a mosquito cell or a Sf21 cell), or mammalian cells (e.g., COS cells, NIH 3T3 cells, or HeLa cells).
• the cell is in vivo.
• the cell is ex vivo , e.g, has been extracted, as an individual cell or as part of an organ or tissue, from a living body or organism for a treatment or procedure, and then returned to the living body or organism.
• the cell is in vitro, e.g., is obtained from a repository.
• the recombinant cell is a eukaryotic cell.
• the recombinant cell is an animal cell.
• the animal cell is a vertebrate animal cell or an invertebrate animal cell.
• the recombinant cell is a mammalian cell.
• Suitable host cells for the expression of glycosylated protein can be derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include insect cells. [0094] Vertebrate cells can also be used as hosts. In this regard, mammalian cell lines that are adapted to grow in suspension can be useful.
• the recombinant cell is an animal cell. In some embodiments, the animal cell is a vertebrate animal cell or an invertebrate animal cell. In some embodiments, the recombinant cell is a mammalian cell. In some embodiments, the animal cell is a human cell. In some embodiments, the animal cell is a non-human animal cell.
• the cell is a non-human primate cell.
• useful mammalian host cell lines are a monkey kidney CV1 cell transformed by SV40 (COS-7), human embryonic kidney cell (e.g., HEK 293 or HEK 293 cell), baby hamster kidney cell (BHK), mouse sertoli cell (e.g., TM4 cells), monkey kidney cell (CV1), human cervical carcinoma cell (HeLa), canine kidney cell (MDCK), buffalo rat liver cell (BRL 3A), human lung cell (W138), human liver cell (Hep G2), mouse mammary tumor (MMT 060562), TRI cell, FS4 cell, Chinese hamster ovary cell (CHO cell), African green monkey kidney cell (Vero cell), human A549 cell, human cervix cell, human CHME5 cell, human PER.C6 cell, NS0 murine myeloma cell, human epidermoid larynx cell, human fibroblast cell, human HUH-7 cell, human
• the recombinant cell is selected from the group consisting of African green monkey kidney cell (Vero cell), baby hamster kidney (BHK) cell, Chinese hamster ovary cell (CHO cell), human A549 cell, human cervix cell, human CHME5 cell, human epidermoid larynx cell, human fibroblast cell, human HEK-293 cell, human HeLa cell, human HepG2 cell, human HUH-7 cell, human MRC-5 cell, human muscle cell, mouse 3T3 cell, mouse connective tissue cell, mouse muscle cell, and rabbit kidney cell.
• Vero cell African green monkey kidney cell
• BHK baby hamster kidney
• CHO cell Chinese hamster ovary cell
• human A549 cell human cervix cell
• human CHME5 cell human epidermoid larynx cell
• human fibroblast cell human HEK-293 cell
• human HeLa cell human HepG2 cell
• human HUH-7 cell human MRC-5 cell
• human muscle cell mouse 3T3 cell
• the recombinant cell is an insect cell, e.g., cell of an insect cell line.
• the recombinant cell is a Sf21 cell.
• Additional suitable insect cell lines include, but are not limited to, cell lines established from insect orders Diptera, Lepidoptera and Hemiptera, and can be derived from different tissue sources.
• the recombinant cell is a cell of a lepidopteran insect cell line. In the past few decades, the availability of lepidopteran insect cell lines has increased at about 50 lines per decade. More information regarding available lepidopteran insect cell lines can be found in, e.g., Lynn D.E., Available lepidopteran insect cell lines.
• the recombinant cell is a mosquito cell, e.g., a cell of mosquito species within Anopheles ( An .), Culex (Cx.) and Aedes ( Stegomyia ) (Ae.) genera.
• mosquito cell lines suitable for the compositions and methods described herein include cell lines from the following mosquito species: Aedes aegypti, Aedes albopictus, Aedes pseudoscutellaris, Aedes triseriatus, Aedes vexans, Anopheles gambiae, Anopheles stephensi, Anopheles albimanus, Culex quinquefasciatus, Culex theileri, Culex tritaeniorhynchus, Culex bitaeniorhynchus, and Toxorhynchites amboinensis.
• mosquito species from the following mosquito species: Aedes aegypti, Aedes albopictus, Aedes pseudoscutellaris, Aedes triseriatus, Aedes vexans, Anopheles gambiae, Anopheles stephensi, Anopheles albimanus, Culex quinque
• Suitable mosquito cell lines include, but are not limited to, CCL-125, Aag-2, RML-12, C6/26, C6/36, C7-10, AP- 61, A.t. GRIP-1, A.t. GRIP-2, UM-AVE1, Mos.55, SualB, 4a-3B, Mos.43, MSQ43, and LSB- AA695BB.
• the mosquito cell is a cell of a C6/26 cell line.
• cell cultures including at least one recombinant cell as disclosed herein, and a culture medium.
• the culture medium can be any suitable culture medium for culturing the cells described herein. Techniques for transforming a wide variety of the above-mentioned host cells and species are known in the art and described in the technical and scientific literature. Accordingly, cell cultures including at least one recombinant cell as disclosed herein are also within the scope of this application. Methods and systems suitable for generating and maintaining cell cultures are known in the art.
• transgenic animals including a nucleic acid construct as described herein.
• the transgenic animal is a vertebrate animal or an invertebrate animal.
• the transgenic animal is an insect.
• the insect is a mosquito.
• the transgenic animal is a mammalian.
• the transgenic mammalian is a non-human mammalian.
• the transgenic animal produces a protein of interest as described herein.
• the transgenic non-human host animals of the disclosure are prepared using standard methods known in the art for introducing exogenous nucleic acid into the genome of a non-human animal.
• the non-human animals of the disclosure are non human primates.
• Other animal species suitable for the compositions and methods of the disclosure include animals that are (i) suitable for transgenesis and (ii) capable of rearranging immunoglobulin gene segments to produce an antibody response. Examples of such species include but are not limited to mice, rats, hamsters, rabbits, chickens, goats, pigs, sheep and cows. Approaches and methods for preparing transgenic non-human animals are known in the art.
• Exemplary methods include pronuclear microinjection, DNA microinjection, lentiviral vector mediated DNA transfer into early embryos and sperm-mediated transgenesis, adenovirus mediated introduction of DNA into animal sperm ( e.g ., in pig), retroviral vectors (e.g. , avian species), somatic cell nuclear transfer (e.g., in goats).
• animal sperm e.g ., in pig
• retroviral vectors e.g. , avian species
• somatic cell nuclear transfer e.g., in goats.
• the animal is a vertebrate animal or an invertebrate animal.
• the animal is an insect. In some embodiments, the insect is a mosquito. In some embodiments, the animal is a mammalian subject. In some embodiments, the mammalian animal is a non-human animal. In some embodiments, the mammalian animal is a non-human primate.
• the transgenic animals of the disclosure can be made using classical random genomic recombination techniques or with more precise techniques such as guide RNA-directed CRISPR/Cas genome editing, or DNA-guided endonuclease genome editing with NgAgo ( Natronobacterium gregoryi Argonaute), or TALENs genome editing (transcription activator-like effector nucleases).
• the transgenic animals of the disclosure can be made using transgenic microinjection technology and do not require the use of homologous recombination technology and thus are considered to be easier to prepare and select than approaches using homologous recombination.
• methods for producing a polypeptide of interest include (i) rearing a transgenic animal as disclosed herein; or (ii) culturing a recombinant cell including a nucleic acid construct as disclosed herein under conditions wherein the transgenic animal or the recombinant cell produces the polypeptide encoded by the GOI.
• kits for producing a polypeptide of interest in a subject include administering to the subject a nucleic acid construct as disclosed herein.
• the subject is vertebrate animal or an invertebrate animal.
• the subject is an insect.
• the insect is a mosquito.
• the subject is a mammalian subject.
• the mammalian subject is a human subject. Accordingly, the recombinant polypeptides produced by the method disclosed herein are also within the scope of the disclosure.
• Non-limiting exemplary embodiments of the disclosed methods for producing a recombinant polypeptide can include one or more of the following features.
• the methods for producing a recombinant polypeptide of the disclosure further include isolating and/or purifying the produced polypeptide.
• the methods for producing a polypeptide of the disclosure further include structurally modifying the produced polypeptide to increase half-life.
• the N-terminus of the produced polypeptide can be further chemically or enzymatically modified to increase half-life.
• the C-terminus of the produced polypeptide is chemically or enzymatically modified to increase half-life.
• Non-limiting examples of chemical and enzymatic modifications suitable for the methods described herein include PEGylation, XTENylation, PASylation®, ELPylation, and HAPylation. Techniques, systems, and reagents suitable for these modifications are known in the art.
• the polypeptide produced by the methods described herein can be PEGylated, XTENylated, PASylated, ELPylated, and/or HAPylated to increase half-life.
• the produced polypeptide is conjugated to another protein or peptide (e.g., serum albumin, an antibody Fc domain, transferrin, GLK, or CTP peptide) to increase half-life.
• compositions can be incorporated into compositions, including pharmaceutical compositions.
• Such compositions generally include one or more of the nucleic acid constructs ⁇ e.g, vectors or srRNA molecules), recombinant cells, recombinant polypeptides described and provided herein, and a pharmaceutically acceptable excipient, e.g, carrier.
• the compositions of the disclosure are formulated for the prevention, treatment, or management of a health condition such as an immune disease or a microbial infection ⁇ e.g, viral infection, micro- fungal infection, or bacterial infection).
• compositions of the disclosure can be formulated as a prophylactic composition, a therapeutic composition, or a pharmaceutical composition comprising a pharmaceutically acceptable excipient, or a mixture thereof.
• the compositions of the present disclosure are formulated for use as a vaccine.
• the compositions of the present application are formulated for use as an adjuvant.
• compositions including a pharmaceutically acceptable excipient and: a) a nucleic acid construct (e.g, a vector or a srRNA molecule) of the disclosure; b) a recombinant cell of the disclosure; and/or c) a recombinant polypeptide of the disclosure.
• a nucleic acid construct e.g, a vector or a srRNA molecule
• compositions including a nucleic acid construct e.g., a vector or a srRNA molecule
• a pharmaceutically acceptable excipient e.g., a nucleic acid construct or a srRNA molecule
• compositions including a recombinant cell as disclosed herein and a pharmaceutically acceptable excipient e.g., a recombinant cell as disclosed herein and a pharmaceutically acceptable excipient.
• the compositions include a recombinant polypeptide of as disclosed herein and a pharmaceutically acceptable excipient.
• the nucleic acid constructs of the disclosure can be used in a naked form or formulated with a delivery vehicle.
• exemplary delivery vehicles suitable for the compositions and methods of the disclosure include, but are not limited to liposomes (e.g, neutral or anionic liposomes), microspheres, immune stimulating complexes (ISCOMS), lipid- based nanoparticles (LNP), solid lipid nanoparticles (SLN), polyplexes, polymer nanoparticles, viral replicon particles (VRPs), or conjugated with bioactive ligands, which can facilitate delivery and/or enhance the immune response.
• liposomes e.g, neutral or anionic liposomes
• ISCOMS immune stimulating complexes
• LNP lipid- based nanoparticles
• SSN solid lipid nanoparticles
• polyplexes polymer nanoparticles
• VRPs viral replicon particles
• conjugated with bioactive ligands which can facilitate delivery and/or enhance the immune response.
• Adjuvants other than liposomes and the like are also used and are known in the art.
• Adjuvants may protect the antigen (e.g., nucleic acid constructs, vectors, srRNA molecules) from rapid dispersal by sequestering it in a local deposit, or they may contain substances that stimulate the host to secrete factors that are chemotactic for macrophages and other components of the immune system. An appropriate selection can be made by those skilled in the art, for example, from those described below.
• a composition of the disclosure can include one or more of the following: physiologic buffer, a liposome, a lipid-based nanoparticle (LNP), a solid lipid nanoparticle (SLN), a polyplex, a polymer nanoparticle, a viral replicon particle (VRP), a microsphere, an immune stimulating complex (ISCOM), a conjugate of bioactive ligand, or a combination of any thereof.
• composition of the disclosure can be formulated in a format to be compatible with its intended route of administration, such as liposome, a lipid-based nanoparticle (LNP), or a polymer nanoparticle. Accordingly, in some embodiments, the compositions of the disclosure that formulated in a liposome. In some embodiments, the compositions of the disclosure that formulated in a lipid-based nanoparticle (LNP). LNPs are generally less immunogenic than viral particles. While many humans have preexisting immunity to viral particles there is no pre existing immunity to LNP. In addition, adaptive immune response against LNP is unlikely to occur which enables repeat dosing of LNP.
• the lipids suitable for the compositions and methods described herein can be cationic lipids, ionizable cationic lipids, anionic lipids, or neutral lipids.
• the LNP of the disclosure can include one or more ionizable lipids.
• ionizable lipid refers to a lipid that is cationic or becomes ionizable (protonated) as the pH is lowered below the pKa of the ionizable group of the lipid, but is more neutral at higher pH values. At pH values below the pKa, the lipid is then able to associate with negatively charged nucleic acids (e.g ., oligonucleotides).
• ionizable lipid includes lipids that assume a positive charge on pH decrease from physiological pH, and any of a number of lipid species that carry a net positive charge at a selective pH, such as physiological pH. Permanently cationic lipids such as DOTMA have proven too toxic for clinical use.
• the ionizable lipid can be present in lipid formulations according to other embodiments, preferably in a ratio of about 30 to about 70 Mol%, in some embodiments, about 30 Mol%, in other embodiments, about 40 Mol%, in other embodiments, about 45 Mol% in other embodiments, about 47.5 Mol% in other embodiments, about 50 Mol%, in still other embodiments, and about 60 Mol% in yet others (“Mol%” means the percentage of the total moles that is of a particular component). The term “about” in this paragraph signifies a plus or minus range of 5 Mol%.
• DODMA or l,2-dioleyloxy-3-dimethylaminopropane
• MC3 ionizable lipid
• Exemplary ionizable lipids suitable for the compositions and methods of the disclosure includes those described in PCT publications WO2020252589A1 and WO2021000041A1, U.S. Patent Nos. 8,450,298 and 10,844,028, and Love K.T.
• the LNP of the disclosure includes one or more lipid compounds described in Love K.T. et al. (2010 supra), such as C 16- 96, Cl 4-110, and Cl 2-200.
• the LNP includes an ionizable cationic lipid selected from the group consisting of ALC-0315, C12-200, LN16, MC3, MD1, SM-102, and a combination of any thereof.
• the LNP of the disclosure includes C12-200 lipid.
• C12-200 lipid is known in the art and described in, e.g., U.S. Patent Nos. 8,450,298 and 10,844,028, which are hereby incorporated by reference in their entirety.
• the C12-200 is combined with cholesterol, C14-PEG2000, and DOPE.
• the C12-200 is combined with DSPC and DMG-PEG2000.
• the LNP of the disclosure includes one or more cationic lipids.
• ionizable cationic lipids include, but are not limited to, 98N12-5, C12-200, C14-PEG2000, DLin-KC2- DMA (KC2), DLin-MC3-DMA (MC3), XTC, MD1, and 7C1.
• a GalNAc moiety is attached to the outside of the LNP and acts as a ligand for uptake into the liver via the asialyloglycoprotein receptor. Any of these cationic lipids can be used to formulate LNP for delivery of the srRNA constructs and nucleic acid constructs of the disclosure.
• the LNP of the disclosure includes one or more neutral lipids.
• neutral lipids suitable for the compositions and methods of the disclosure include DPSC, DPPC, POPC, DOPE, and SM.
• the LNP of the disclosure includes one or more ionizable lipid compounds described in PCT publications WO2020252589A1 and W02021000041A1.
• lipids suitable for use to produce LNPs include DOTMA, DOSPA, DOTAP, DMRTE, DC-cholesterol, DOTAP-cholesterol, GAP- DMORIE-DPyPE, and GL67A-DOPE-DMPE-polyethylene glycol (PEG).
• cationic lipids include 98N12-5, C12-200, C14-PEG2000, DLin-KC2- DMA (KC2), DLin-MC3-DMA (MC3), XTC, MD1, 7C1, and a combination of any thereof.
• Non-limiting examples of neutral lipids include DPSC, DPPC, POPC, DOPE, and SM.
• Non-limiting examples of PEG-modified lipids include PEG-DMG, PEG-CerC14, and PEG-CerC20.
• the mass ratio of lipid to nucleic acid in the LNP delivery system is about 100:1 to about 3:1, about 70:1 to 10:1, or 16:1 to 4:1. In some embodiments, the mass ratio of lipid to nucleic acid in the LNP delivery system is about 16:1 to 4:1. In some embodiments, the mass ratio of lipid to nucleic acid in the LNP delivery system is about 20: 1. In some embodiments, the mass ratio of lipid to nucleic acid in the LNP delivery system is about 8:1.
• the lipid-based nanoparticles have an average diameter of less than about 1000 nm, about 500 nm, about 250 nm, about 200 nm, about 150 nm, about 100 nm, about 75 nm, about 50 nm, or about 25 nm. In some embodiments, the LNPs have an average diameter ranging from about 70 nm to 100 nm. In some embodiments, the LNPs have an average diameter ranging from about 88 nm to about 92 nm, from 82 nm to about 86 nm, or from about 80 nm to about 95 nm.
• the compositions of the disclosure that formulated in a polymer nanoparticle.
• the compositions are immunogenic compositions, e.g ., composition that can stimulate an immune response in a subject.
• the immunogenic compositions are formulated as a vaccine.
• the pharmaceutical compositions are formulated as an adjuvant.
• the immunogenic compositions are formulated as a biotherapeutic, e.g., vehicle for gene delivery of different molecules with bioactivity.
• biotherapeutic include cytokines, chemokines, and other soluble immunomodulators, enzymes, peptide and protein agonists, peptide and protein antagonists, hormones, receptors, antibodies and antibody-derivatives, growth factors, transcription factors, and gene silencing/editing molecules.
• the pharmaceutical compositions are formulated as an adjuvant.
• the immunogenic compositions are substantially non- immunogenic or minimally immunogenic (e.g. compositions that minimally stimulate an immune response in a subject.
• the non-immunogenic or minimally immunogenic compositions are formulated as a biotherapeutic.
• the pharmaceutical compositions are formulated for one or more of intranasal administration, transdermal administration, intraperitoneal administration, intramuscular administration, intranodal administration, intratumoral administration, intraarticular administration, intravenous administration, subcutaneous administration, intravaginal administration, and oral administration.
• compositions suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
• suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM. (BASF, Parsippany, N.J.), or phosphate buffered saline (PBS).
• the composition should be sterile and should be fluid to the extent that easy syringeability exists. It can be stable under the conditions of manufacture and storage, and can be preserved against the contaminating action of microorganisms such as bacteria and fungi.
• the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
• the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants, e.g., sodium dodecyl sulfate.
• surfactants e.g., sodium dodecyl sulfate.
• Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
• isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, and/or sodium chloride in the composition.
• Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
• Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
• dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic dispersion medium and the required other ingredients from those enumerated above.
• the pharmaceutical compositions of the disclosure are formulated for inhalation, such as an aerosol, spray, mist, liquid, or powder.
• Administration by inhalation may be in the form of either dry powders or aerosol formulations, which are inhaled by a subject (e.g., a patient) either through use of an inhalation device, e.g., a microspray, a pressurized metered dose inhaler, or nebulizer.
• the composition is formulated for one or more of intranasal administration, transdermal administration, intramuscular administration, intranodal administration, intravenous administration, intraperitoneal administration, oral administration, intravaginal, or intra-cranial administration.
• the administered composition results in an increased production of interferon in the subject.
• nucleic acid constructs e.g., vectors or srRNA molecules
• recombinant cells e.g., recombinant polypeptides, and/or pharmaceutical compositions
• relevant health conditions such as proliferative disorders (e.g., cancers), infectious diseases (e.g., acute infections, chronic infections, or viral infections), rare diseases, and/or autoimmune diseases, and/or inflammatory diseases.
• the nucleic acid constructs e.g, vectors or srRNA molecules
• recombinant cells e.g., recombinant polypeptides, and/or pharmaceutical compositions as described herein
• the nucleic acid constructs e.g, vectors or srRNA molecules
• recombinant cells e.g., recombinant polypeptides, and/or pharmaceutical compositions as described herein
• compositions described herein for their capacity to confer a pharmacodynamic effect can be carried out in vivo and/or ex vivo.
• pharmacodynamic effects that can be analyzed include: immunogenicity effect (e.g., eliciting an immune response in vivo), a biomarker response, a therapeutic effect, a prophylactic effect, a desired effect, an undesired effect, an adverse effect, and effect in a disease model.
• the assessment of pharmacodynamic effects includes assessing induction of an immune response in vivo /see, e.g., Examples 1-4).
• the assessment of pharmacodynamic effects includes assessing induction of cytokine pathways that can potentiate an immune response and prevent angiogenesis and metastasis /see, e.g., Examples 1-4).
• the nucleic acid constmcts e.g ., vectors or srRNA molecules
• recombinant cells e.g ., recombinant cells
• recombinant polypeptides e.g., recombinant polypeptides
• pharmaceutical compositions as described herein can be incorporated into therapeutic agents for use in methods of treating a subject who has, who is suspected of having, or who may be at high risk for developing one or more relevant health conditions or diseases.
• Exemplary health conditions or diseases can include, without limitation, cancers, immune diseases, autoimmune diseases, inflammatory diseases, gene therapy, gene replacement, cardiovascular diseases, age-related pathologies, rare disease, acute infection, and chronic infection.
• the subject is a patient under the care of a physician.
• autoimmune diseases suitable for the methods of the disclosure include, but are not limited to, rheumatoid arthritis, osteoarthritis, Still’s disease, Familiar Mediterranean Fever, systemic sclerosis, multiple sclerosis, ankylosing spondylitis, Hashimoto's thyroiditis, systemic lupus erythematosus, Sjogren's syndrome, diabetic retinopathy, diabetic vasculopathy, diabetic neuralgia, insulitis, psoriasis, alopecia areata, warm and cold autoimmune hemolytic anemia (AIHA), pernicious anemia, acute inflammatory diseases, autoimmune adrenalitis, chronic inflammatory demyelinating polyneuropathy (CIDP), Lambert-Eaton syndrome, lichen sclerosis, Lyme disease, Graves disease, Behpefs disease, Meniere's disease, reactive arthritis (Reiter's syndrome), Churg-Strauss syndrome, Cogan syndrome, CREST syndrome, pemph
• Non-limiting examples of infection suitable for the methods of the disclosure include infections with viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis B virus (HCV), Cytomegalovirus (CMV), respiratory syncytial virus (RSV), human papillomavirus (HPV), Epstein-Barr virus (EBV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East Respiratory Syndrome (MERS), influenza virus, and Ebola virus.
• viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis B virus (HCV), Cytomegalovirus (CMV), respiratory syncytial virus (RSV), human papillomavirus (HPV), Epstein-Barr virus (EBV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), severe acute respiratory syndrome coronavirus (S
• Additional infections suitable for the methods of the disclosure include infections with intracellular parasites such as Leishmania, Rickettsia, Chlamydia, Coxiella, Plasmodium, Brucella, mycobacteria, Listeria, Toxoplasma and Trypanosoma.
• intracellular parasites such as Leishmania, Rickettsia, Chlamydia, Coxiella, Plasmodium, Brucella, mycobacteria, Listeria, Toxoplasma and Trypanosoma.
• the nucleic acid constructs can be useful in the treatment and/or prevention of immune diseases, autoimmune diseases, or inflammatory diseases such as, for example, glomerulonephritis, inflammatory bowel disease, nephritis, peritonitis, psoriatic arthritis, osteoarthritis, Still’s disease, Familiar Mediterranean Fever, systemic scleroderma and sclerosis, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, acute lung injury, meningitis, encephalitis, uveitis, multiple myeloma, glomerulonephritis, nephritis, asthma, atherosclerosis, leukocyte adhesion deficiency, multiple sclerosis, Raynaud's syndrome, Sjogren's syndrome, juvenile onset
• IBD inflammatory bowel disease
• Crohn's disease Crohn's disease
• ulcerative colitis acute lung injury, meningitis, encephalitis, uveitis,
• Non-limiting examples of inflammatory suitable for the methods of the disclosure include inflammatory diseases such as asthma, inflammatory bowel disease (IBD), chronic colitis, splenomegaly, and rheumatoid arthritis.
• IBD inflammatory bowel disease
• chronic colitis splenomegaly
• rheumatoid arthritis rheumatoid arthritis
• a composition including: a) a nucleic acid constmct of the disclosure; b) a recombinant cell of the disclosure; c) a recombinant polypeptide of the disclosure; and/or d) a pharmaceutical composition of the disclosure.
• a composition including: a) a nucleic acid construct of the disclosure; b) a recombinant cell of the disclosure; c) a recombinant polypeptide of the disclosure; and/or d) a pharmaceutical composition of any one of the disclosure.
• the health condition is a proliferative disorder or a microbial infection (e.g., bacterial infection, micro-fungal infection, or viral infection).
• the subject has or is suspected of having a condition associated with proliferative disorder or a microbial infection (e.g., bacterial infection, micro-fungal infection, or viral infection).
• the health condition is a rare disease, e.g, a disease or condition that affects less than 200,000 people in the United States, as defined by The Orphan Drug Act (www.fda.gov/patients/rare-diseases-fda) and/or an inflammatory and/or autoimmune disorder.
• the subject has or is suspected of having a condition associated with an inflammatory and/or autoimmune disorder and/or a rare disease (e.g. including but not limited to Familial Mediterranean Fever or adult onset Still’s disease).
• the disclosed composition is formulated to be compatible with its intended route of administration.
• the nucleic acid constructs, recombinant cells, recombinant polypeptides, and/or pharmaceutical compositions of the disclosure may be given orally or by inhalation, but it is more likely that they will be administered through a parenteral route.
• parenteral routes of administration include, for example, intravenous, intranodal, intradermal, subcutaneous, transdermal (topical), transmucosal, intravaginal, and rectal administration.
• Solutions or suspensions used for parenteral application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
• a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents
• antibacterial agents such as benzyl alcohol or methyl parabens
• antioxidants such as ascorbic acid or sodium bisulfite
• chelating agents such as ethylenediaminete
• pH can be adjusted with acids or bases, such as mono- and/or di basic sodium phosphate, hydrochloric acid or sodium hydroxide (e.g., to a pH of about 7.2-7.8, e.g ., 7.5).
• acids or bases such as mono- and/or di basic sodium phosphate, hydrochloric acid or sodium hydroxide (e.g., to a pH of about 7.2-7.8, e.g ., 7.5).
• the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
• Dosage, toxicity and therapeutic efficacy of such subject nucleic acid constructs can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g, for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
• the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50.
• Compounds that exhibit high therapeutic indices are generally suitable. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.
• the data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans.
• the dosage of such compounds lies generally within a range of circulating concentrations that include the ED50 with little or no toxicity.
• the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
• the therapeutically effective dose can be estimated initially from cell culture assays.
• a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (e.g, the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture.
• IC50 e.g, the concentration of the test compound which achieves a half-maximal inhibition of symptoms
• levels in plasma may be measured, for example, by high performance liquid chromatography.
• compositions described herein e.g., nucleic acid constructs (e.g., vectors or srRNA molecules), recombinant cells, recombinant polypeptides, and/or pharmaceutical compositions, can be administered one from one or more times per day to one or more times per week; including once every other day.
• nucleic acid constructs e.g., vectors or srRNA molecules
• recombinant cells e.g., vectors or srRNA molecules
• recombinant cells e.g., recombinant polypeptides, and/or pharmaceutical compositions
• pharmaceutical compositions can be administered one from one or more times per day to one or more times per week; including once every other day.
• treatment of a subject with a therapeutically effective amount of the subject multivalent polypeptides and multivalent antibodies of the disclosure can include a single treatment or, can include a series of treatments.
• the compositions are administered every 8 hours for five days, followed by a rest period of 2 to 14 days, e.g., 9 days, followed by an additional five days of administration every 8 hours.
• the therapeutically effective amount of a nucleic acid construct or recombinant polypeptide of the disclosure depends on the nucleic acid construct or recombinant polypeptide selected. For instance, single dose amounts in the range of approximately 0.001 to 0.1 mg/kg of patient body weight can be administered. In some embodiments, about 0.005, 0.01, 0.05 mg/kg may be administered. In some embodiments, single dose amounts in the range of approximately 0.03 pg to 300 pg/kg of patient body weight can be administered. In some embodiments, single dose amounts in the range of approximately 0.3 mg to 3 mg/kg of patient body weight can be administered.
• a therapeutically effective amount includes an amount of a therapeutic composition that is sufficient to promote a particular effect when administered to a subject, such as one who has, is suspected of having, or is at risk for a health condition, e.g., a disease or infection.
• an effective amount includes an amount sufficient to prevent or delay the development of a symptom of the disease or infection, alter the course of a symptom of the disease or infection (for example but not limited to, slow the progression of a symptom of the disease or infection), or reverse a symptom of the disease or infection. It is understood that for any given case, an appropriate effective amount can be determined by one of ordinary skill in the art using routine experimentation.
• the efficacy of a treatment including a disclosed therapeutic composition for the treatment of disease or infection can be determined by the skilled clinician. However, a treatment is considered effective treatment if at least any one or all of the signs or symptoms of disease or infection are improved or ameliorated. Efficacy can also be measured by failure of an individual to worsen as assessed by hospitalization or need for medical interventions (e.g., progression of the disease or infection is halted or at least slowed). Methods of measuring these indicators are known to those of skill in the art and/or described herein.
• Treatment includes any treatment of a disease or infection in a subject or an animal (some non-limiting examples include a human, or a mammal) and includes: (1) inhibiting the disease or infection, e.g., arresting, or slowing the progression of symptoms; or (2) relieving the disease or infection, e.g., causing regression of symptoms; and (3) preventing or reducing the likelihood of the development of symptoms.
• the nucleic acid constructs e.g, vectors or srRNA molecules
• recombinant cells e.g., recombinant cells
• recombinant polypeptides e.g., pharmaceutical compositions of the disclosure
• a subject can be immunized through an initial series of injections (or administration through one of the other routes described below) and subsequently given boosters to increase the protection afforded by the original series of administrations.
• the initial series of injections and the subsequent boosters are administered in such doses and over such a period of time as is necessary to stimulate an immune response in a subject.
• the administered composition results in an increased production of interferon in the subject, for example, by at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 100% as compared to interferon production in a subject that has not been administered with the composition.
• the subject is a mammal. In some embodiments, the mammal is a human subject.
• pharmaceutically acceptable carriers suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
• the composition must be sterile and must be fluid to the extent that easy syringeability exists.
• the composition must further be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
• the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, etc.), suitable mixtures thereof, and vegetable oils.
• the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
• a coating such as lecithin
• surfactants for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
• Sterile injectable solutions can be prepared by incorporating the nucleic acid constructs (e.g., vectors or srRNA molecules), recombinant cells, and/or recombinant polypeptides in the required mount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
• nucleic acid constructs e.g., vectors or srRNA molecules
• recombinant cells e.g., recombinant cells
• polypeptides e.g., recombinant polypeptides
• nucleic acid constructs e.g., vectors or srRNA molecules
• recombinant cells e.g., recombinant polypeptides, and/or pharmaceutical compositions
• they may be orally administered, for example, with an inert diluent or an assimilable edible carrier.
• the nucleic acid constructs e.g., vectors or srRNA molecules
• recombinant cells, recombinant polypeptides, and/or pharmaceutical compositions and other ingredients may also be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the individual's diet.
• the active compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
• the nucleic acid constructs e.g, vectors or srRNA molecules
• recombinant polypeptides of the disclosure can be delivered to a cell or a subject by a lipid-based nanoparticle (LNP).
• LNP are generally less immunogenic than viral particles. While many humans have preexisting immunity to viral particles there is no pre-existing immunity to LNP. In addition, adaptive immune response against LNP is unlikely to occur which enables repeat dosing of LNP.
• ionizable cationic lipids have been developed for use in LNP. These include C12-200, MC3, LN16, and MD1 among others.
• a GalNAc moiety is attached to the outside of the LNP and acts as a ligand for uptake into the liver via the asialyloglycoprotein receptor. Any of these cationic lipids can be used to formulate LNP for delivery of the nucleic acid constructs (e.g, vectors or srRNA molecules) and recombinant polypeptides of the disclosure to the liver.
• a LNP refers to any particle having a diameter of less than 1000 nm, 500 nm, 250 nm, 200 nm, 150 nm, 100 nm, 75 nm, 50 nm, or 25 nm.
• a nanoparticle can range in size from 1-1000 nm, 1-500 nm, 1-250 nm, 25-200 nm, 25-100 nm, 35- 75 nm, or 25-60 nm.
• LNPs can be made from cationic, anionic, or neutral lipids.
• Neutral lipids such as the fusogenic phospholipid DOPE or the membrane component cholesterol, can be included in LNPs as 'helper lipids' to enhance transfection activity and nanoparticle stability.
• Limitations of cationic lipids include low efficacy owing to poor stability and rapid clearance, as well as the generation of inflammatory or anti-inflammatory responses.
• LNPs can also have hydrophobic lipids, hydrophilic lipids, or both hydrophobic and hydrophilic lipids.
• lipids or combination of lipids that are known in the art can be used to produce a LNP.
• lipids suitable for use to produce LNPs include DOTMA, DOSPA, DOTAP, DMRIE, DC-cholesterol, DOTAP-cholesterol, GAP-DMORIE- DPyPE, and GL67A-DOPE-DMPE-polyethylene glycol (PEG).
• Non-limiting examples of cationic lipids include 98N12-5, C12-200, DLin-KC2-DMA (KC2), DLin-MC3-DMA (MC3), XTC, MD1, and 7C1.
• Non-limiting examples of neutral lipids include DPSC, DPPC, POPC, DOPE, and SM.
• Non-limiting examples of PEG-modified lipids include PEG-DMG, PEG- CerC14, and PEG-CerC20.
• the lipids can be combined in any number of molar ratios to produce a LNP.
• the polynucleotide(s) can be combined with lipid(s) in a wide range of molar ratios to produce a LNP.
• the therapeutic compositions described herein e.g., nucleic acid constructs (e.g., vectors or srRNA molecules), recombinant cells, recombinant polypeptides, and/or pharmaceutical compositions are incorporated into therapeutic compositions for use in methods of preventing or treating a subject who has, who is suspected of having, or who may be at high risk for developing a cancer, an autoimmune disease, and/or an infection.
• nucleic acid constructs e.g., vectors or srRNA molecules
• recombinant cells e.g., recombinant cells
• recombinant polypeptides e.g., recombinant polypeptides, and/or pharmaceutical compositions are incorporated into therapeutic compositions for use in methods of preventing or treating a subject who has, who is suspected of having, or who may be at high risk for developing a cancer, an autoimmune disease, and/or an infection.
• the therapeutic compositions described herein e.g., nucleic acid constructs (e.g., vectors or srRNA molecules), recombinant cells, recombinant polypeptides, and/or pharmaceutical compositions are incorporated into therapeutic compositions for use in methods of preventing or treating a subject who has, who is suspected of having, or who may be at high risk for developing a microbial infection.
• the microbial infection is a bacterial infection.
• the microbial infection is a fungal infection.
• the microbial infection is a viral infection.
• a composition according to the present disclosure is administered to the subject individually as a single therapy (monotherapy) or as a first therapy in combination with at least one additional therapies (e.g, second therapy).
• the second therapy is selected from the group consisting of chemotherapy, radiotherapy, immunotherapy, hormonal therapy, toxin therapy, targeted therapy, and surgery.
• the second therapy is selected from the group consisting of chemotherapy, radiotherapy, immunotherapy, hormonal therapy, toxin therapy or surgery.
• the first therapy and the second therapy are administered concomitantly.
• the first therapy is administered at the same time as the second therapy.
• the first therapy and the second therapy are administered sequentially.
• the first therapy is administered before the second therapy. In some embodiments, the first therapy is administered after the second therapy. In some embodiments, the first therapy is administered before and/or after the second therapy. In some embodiments, the first therapy and the second therapy are administered in rotation. In some embodiments, the first therapy and the second therapy are administered together in a single formulation.
• kits for the practice of a method described herein as well as written instructions for making and using the same are provided herein.
• some embodiments of the disclosure provide kits for modulating an immune response in a subject.
• kits for the prevention of a health condition in a subject in need thereof relate to kits for methods of treating a health condition in a subject in need thereof.
• kits that include one or more of the nucleic acid constructs (e.g., vectors or srRNA molecules), recombinant cells, recombinant polypeptides, and/or pharmaceutical compositions as provided and described herein, as well as written instructions for making and using the same.
• kits of the disclosure further include one or more means useful for the administration of any one of the provided nucleic acid constructs (e.g., vectors or srRNA molecules), recombinant cells, recombinant polypeptides, and/or pharmaceutical compositions to a subject.
• the kits of the disclosure further include one or more syringes (including pre- filled syringes) and/or catheters (including pre-filled syringes) used to administer any one of the provided nucleic acid constructs (e.g ., vectors or srRNA molecules), recombinant cells, recombinant polypeptides, and/or pharmaceutical compositions to a subject.
• a kit can have one or more additional therapeutic agents that can be administered simultaneously or sequentially with the other kit components for a desired purpose, e.g., for diagnosing, preventing, or treating a condition in a subject in need thereof.
• kits can further include one or more additional reagents, where such additional reagents can be selected from: dilution buffers; reconstitution solutions, wash buffers, control reagents, control expression vectors, negative controls, positive controls, reagents suitable for in vitro production of the provided nucleic acid constructs (e.g., vectors or srRNA molecules), recombinant cells, recombinant polypeptides, and/or pharmaceutical compositions of the disclosure.
• additional reagents can be selected from: dilution buffers; reconstitution solutions, wash buffers, control reagents, control expression vectors, negative controls, positive controls, reagents suitable for in vitro production of the provided nucleic acid constructs (e.g., vectors or srRNA molecules), recombinant cells, recombinant polypeptides, and/or pharmaceutical compositions of the disclosure.
• the components of a kit can be in separate containers. In some other embodiments, the components of a kit can be combined in a single container. Accordingly, in some embodiments of the disclosure, the kit includes one or more of the nucleic acid constructs (e.g, vectors or srRNA molecules), recombinant cells, recombinant polypeptides, and/or pharmaceutical compositions as provided and described herein in one container (e.g, in a sterile glass or plastic vial) and a further therapeutic agent in another container (e.g, in a sterile glass or plastic vial).
• the nucleic acid constructs e.g, vectors or srRNA molecules
• recombinant cells e.g, recombinant cells
• recombinant polypeptides e.g., and/or pharmaceutical compositions as provided and described herein in one container (e.g, in a sterile glass or plastic vial) and a further therapeutic agent in another container (e.g, in a
• the kit includes a combination of the compositions described herein, including one or more nucleic acid constructs (e.g, vectors or srRNA molecules), recombinant cells, and/or recombinant polypeptides of the disclosure in combination with one or more additional therapeutic agents formulated together, optionally, in a pharmaceutical composition, in a single, common container.
• nucleic acid constructs e.g, vectors or srRNA molecules
• recombinant cells e.g., recombinant cells
• polypeptides of the disclosure in combination with one or more additional therapeutic agents formulated together, optionally, in a pharmaceutical composition, in a single, common container.
• the kit can include a device (e.g, an injection device or catheter) for performing such administration.
• the kit can include one or more hypodermic needles or other injection devices as discussed above containing one or more nucleic acid constructs (e.g, vectors or srRNA molecules), recombinant cells, and/or recombinant polypeptides of the disclosure.
• kits can further include instructions for using the components of the kit to practice the methods disclosed herein.
• the kit can include a package insert including information concerning the pharmaceutical compositions and dosage forms in the kit. Generally, such information aids patients and physicians in using the enclosed pharmaceutical compositions and dosage forms effectively and safely.
• the following information regarding a combination of the disclosure may be supplied in the insert: pharmacokinetics, pharmacodynamics, clinical studies, efficacy parameters, indications and usage, contraindications, warnings, precautions, adverse reactions, overdosage, proper dosage and administration, how supplied, proper storage conditions, references, manufacturer/distributor information and intellectual property information.
• the instructions for practicing the methods are generally recorded on a suitable recording medium.
• the instmctions can be printed on a substrate, such as paper or plastic, etc.
• the instructions can be present in the kit as a package insert, in the labeling of the container of the kit or components thereof (e.g., associated with the packaging or sub packaging), etc.
• the instructions can be present as an electronic storage data file present on a suitable computer readable storage medium, e.g. CD-ROM, diskette, flash drive, etc.
• the actual instmctions are not present in the kit, but means for obtaining the instmctions from a remote source (e.g, via the internet), can be provided.
• An example of this embodiment is a kit that includes a web address where the instmctions can be viewed and/or from which the instmctions can be downloaded. As with the instmctions, this means for obtaining the instmctions can be recorded on a suitable substrate.
• This Example describes the results of experiments performed to construct a base EEEV vector (e.g., without a heterologous gene) that were subsequently used for construction of an EEEV vector with expression of a gene of interest (e.g, hemagglutinin precursor (HA) of the influenza A virus H5N1).
• a gene of interest e.g, hemagglutinin precursor (HA) of the influenza A virus H5N1.
• the base EEEV vector (i.e. without a heterologous gene of interest) was constructed as follows: The base EEEV vector (see, e.g, FIG. 2A) was synthesized de novo in four ⁇ 4 kb parts (Twist Bioscience) from a reference sequence (Genbank EF151502) with several modifications. Silent G301A, G4516A, and G7399A mutations were incorporated to eliminate Sapl restriction enzyme cut sites. A silent A3550C mutation was incorporated to eliminate a Spe I restriction enzyme cut site. A silent G5725A mutation was incorporated to eliminate an Esp3l restriction enzyme cut site.
• a unique restriction enzyme cut site (Spe I, 5’- A’CTAG,T-3’) was incorporated in place of the coding sequence of the native EEEV structural genes (where the 5’ A matches the location of the structural polyprotein ATG start codon, and the 3’ T matches the location of the structural polyprotein stop codon TAA).
• a 5’ adaptor sequence (5’- CTGGAGACGTGGAGGAGAACCCTGGACCT-3 ’ ; SEQ ID NO: 3) was inserted upstream of the Spel site, and a 3’ adaptor sequence (5’-
• GACCGCTACGCCCCAATGACCCGACCAGC-3’; SEQ ID NO: 4 was inserted downstream of the Spe I site for subsequent Gibson Assembly® procedures (Gibson el cil, Nat. Methods 6, 343-345, 2009).
• a bacteriophage T7 RNA polymerase promoter (5 - TAATACGACTCACTATAG-3’; SEQ ID NO: 5) was included upstream of the EEEV genome sequence, and downstream contained a poly(A) sequence followed by a Sapl site, which cuts upstream of the recognition site.
• T7 terminator sequence 5’-AACCCCTCTCTAAACGGAGGGGTTTTTTT-3’; SEQ ID NO: 6
• SEQ ID NO: 6 a unique restriction enzyme cut site
• EEEV vector containing a heterologous gene was carried out as follows: the EEEV vector described in FIG. 2B was constructed by the linearization of the empty EEEV vector in FIG. 2A by Spe I digestion.
• the hemagglutinin (HA) gene from influenza (Genbank AY651334) was codon optimized/refactored for human expression in silico and synthesized de novo (IDT).
• the synthetic product was amplified using primers which added the 5’ and 3’ adaptor sequences to the end of the HA gene.
• the digestion product and the PCR product were combined by Gibson Assembly® procedure to result in the final vector.
• This Example describes the results of in vitro experiments performed to evaluate expression levels of the synthetic EEEV replicon constructs (e.g., self-replicating RNAs) described in Example 1 above, and to investigate various differential behavior thereof (e.g., replication and protein expression).
• synthetic EEEV replicon constructs e.g., self-replicating RNAs
• srRNA was prepared by in vitro transcription from a Sapl- linearized plasmid template with bacteriophage T7 polymerase with either a 5’ ARCA cap (HiScribeTM T7 ARCA mRNA Kit, NEB) or by uncapped transcription (HiScribeTM T7 High Yield RNA Synthesis Kit, NEB) followed by addition of a 5’ cap 1 (Vaccinia Capping System, mRNA Cap 2 -O-Methyl transferase, NEB). srRNA was then purified using phenol/chloroform extraction, LiCl precipitation, or column purification (Monarch® RNA Cleanup Kit, NEB). srRNA concentration was determined by absorbance at 260 nm (Nanodrop, Thermo Fisher Scientific).
• srRNA was transformed by electroporation into BHK-21 or Vero cells (e.g, 4D-NucleofectorTM, Lonza). At 18-20 hours following transformation, the cells were fixed and permeabilized (eBioscienceTM Foxp3 / Transcription Factor Staining Buffer Set, Invitrogen) and subsequently stained using a PE-conjugated anti-dsRNA mouse monoclonal antibody (J2, Scicons) to quantify the frequency of dsRNA+ cells and the mean fluorescence intensity (MFI) of dsRNA in individual cells by fluorescence flow cytometry.
• J2, Scicons PE-conjugated anti-dsRNA mouse monoclonal antibody
• Protein expression was transformed by electroporation into BHK-21 or Vero cells (e.g., 4D-NucleofectorTM, Lonza). At 18-20 hours following transformation, the cells were fixed and permeabilized (eBioscienceTM Foxp3 / Transcription Factor Staining Buffer Set, Invitrogen) and stained using an APC-conjugated anti-HA mouse monoclonal antibody (2B7, Abeam) to quantify the frequency of cells expressing the HA protein and the mean fluorescence intensity (MFI) of the HA protein in individual cells by fluorescence flow cytometry.
• B7 APC-conjugated anti-HA mouse monoclonal antibody
• srRNA constructs that exhibit RNA replication for example detected by flow cytometry as described above can be considered as promising practical vectors to induce a pharmacokinetic effect.
• srRNA constructs that exhibit protein expression of transgene(s) can be considered as promising practical vectors to induce additional pharmacokinetic effects (e.g. to elicit an immune response in a host).
• This Example describes the results of in vitro experiments performed to evaluate expression levels of synthetic EEEV self-replicating RNAs (srRNAs) and to investigate various differential behavior thereof (e.g., replication and protein expression).
• srRNAs synthetic EEEV self-replicating RNAs
• srRNAs derived from the EEEV strain FL93-939 were designed and subsequently evaluated, including control VEEV srRNAs expressing two reference transgenes (RBI296, RBI298), VEEV srRNAs encoding both IL-1RA and EL-12 in two configurations (RBI299, RBI300), and EEEV srRNAs encoding botii IL-1RA and IL-12 in two configurations (RBI305, RBI306)
• srRNA was prepared by in vitro transcription from a Sapl- linearized plasmid template with bacteriophage T7 polymerase by uncapped transcription (HiScribeTM T7 High Yield RNA Synthesis Kit, NEB) followed by addition of a 5’ cap 1 (Vaccinia Capping System, mRNA Cap 2' -O-Methyl transferase, NEB). srRNA was then purified by LiCl precipitation. srRNA concentration was determined by absorbance at 260 nm (Nanodrop, Thermo Fisher Scientific).
• Protein expression srRNA was transformed by electroporation into BHK-21 cells ( 4D-Nucleofector TM, Lonza). At 24 and 48 hours following transformation, conditioned media was collected from the cells. Secreted IL-1RA was evaluated in a bioactivity assay by preincubating HEK-BlueTM IL-1R cells (InvivoGen) with a range of concentrations of recombinant IL-1RA (Peprotech) or conditioned media. Recombinant IL-1B (Invivogen) was added to the cells and incubated overnight then the SEAP reporter was quantified using QUANTI-BlueTM (Invivogen) (see, e.g., FIG 4A).
• IL-12 was evaluated in a bioactivity assay by incubating a range of concentrations of recombinant IL-12 (Peprotech) or conditioned media on IL-12 bioassay cells (Promega) overnight in DMEM then the Luciferase reporter was quantified using Bio-GloTM Luciferase (Promega) (see, e.g., FIG 4B).
• srRNA constructs that exhibit protein expression of transgene(s) can be considered as promising practical vectors to induce pharmacokinetic effects (e.g. to elicit an immune response in a host).
• the evaluation of activity of the proteins expressed from srRNA vectors is important to verify that the expressed protein retains intended functions for eliciting pharmacokinetic effects. Differences in relative protein expression between vectors can offer advantages (e.g. lower doses to achieve equivalent levels of protein expression).
• This Example describes the results of in vivo experiments performed to evaluate any differential immune responses following vaccination with the synthetic EEEV replicon constmcts (e.g ., self-replicating RNAs) described in Examples 1 and 2 above (e.g, both unformulated and LNP formulated vectors).
• synthetic EEEV replicon constmcts e.g ., self-replicating RNAs
• mice and injections Female C57BL/6 or BALB/c mice are purchased from Charles River Labs or Jackson Laboratories. On day of dosing, between 0.1-10 pg of material is injected intramuscularly split into both quadricep muscles. Vectors are administered either unformulated in saline, or LNP -formulated. Animals are monitored for body weight and other general observations throughout the course of the study. For immunogenicity studies, animals are dosed on Day 0 and Day 21. Spleens are collected at Day 14 and/or 35, and serum is isolated at Days 14, and/or 35.
• srRNA-based vaccines In addition to an infectious disease antigen, immunogenicity of srRNA-based vaccines to cancer antigens was assessed (FIG 6A-6C).
• Each srRNA vaccine co-encoded sequences from ESR1, HER2, and HER3.
• Splenic T cell responses to these three antigens were determined using ELISpot analysis in mice having received two immunizations. Robust T cell responses were observed to all three targets, while the pattern of responses differed between srRNA vectors (see, e.g., FIG 6A-6C).
• mice are dosed on Day 0, and protein expression is assessed on Days 3, and/or 7 by serum ELISA.
• srRNAs encoding human IL12A and IL12B to form IL-12p70 were administered intramuscularly in mice. Serum was collected at day 7 to detect systemic levels of protein (see, e.g., FIG 7).
• animals were administered a srRNA derived from EEEV FL93-939 with coding sequences for species-matched mouse 1112a and II 12b genes. Functionality of IL- 12 is measured by assessing induction of IFNy, as a downstream pharmacodynamic marker. Sera from mice at Day 3 following administration of the srRNA showed detectable levels of IFNy (see, e-g, FIG. 8).
• LNP formulation e.g ., self-replicating RNA
• replicon RNA e.g ., self-replicating RNA
• LNP are composed of an ionizable lipid, cholesterol, PEG-2K, and DOPE
• ELISpot To measure the magnitude of antigen-specific T cell responses, IFNy ELISpot analysis is performed using Mouse IFNy ELISpot PLUS Kit (HRP) (MabTech) as per manufacturer’s instructions. In brief, splenocytes are isolated and resuspended to a concentration of 2-5 x 10 6 cells/mL in media containing peptides representing either peptide pools corresponding to rabies glycoprotein G, ESR1, HER2, or HER3, PMA/ionomycin as a positive control, or DMSO as a mock stimulation.
• HRP Mouse IFNy ELISpot PLUS Kit
• Antibodies Neutralizing antibody responses to rabies virus are measured using rapid fluorescent focus inhibition test. In brief, serum dilutions are mixed with a standard amount of live rabies virus and incubated. If neutralizing anti -rabies antibodies are present, they will neutralize the virus. Next, cultured cells are added and the serum/vims/cells are incubated together. Uncoated rabies virus (i.e. that has not been neutralized by antibodies), will infect the cells and this can be visualized by microscopy. Calculation of the endpoint titer is made from the percent of virus infected cells observed on the slide.
• ELISA Detection of human IL-12p70 was done using a commercial kit Human IL- 12 p70 DuoSet ELISA from R&D Systems (DY1270). Detection of mouse serum IFNy was done using a commercial kit from R&D Systems (Mouse IFN-gamma DuoSet).

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Genetics & Genomics (AREA)
• General Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Medicinal Chemistry (AREA)
• Organic Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Biotechnology (AREA)
• Zoology (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Wood Science & Technology (AREA)
• Biochemistry (AREA)
• Biomedical Technology (AREA)
• Molecular Biology (AREA)
• General Engineering & Computer Science (AREA)
• Virology (AREA)
• Microbiology (AREA)
• Biophysics (AREA)
• Physics & Mathematics (AREA)
• Immunology (AREA)
• Plant Pathology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Mycology (AREA)
• Environmental Sciences (AREA)
• Nanotechnology (AREA)
• Optics & Photonics (AREA)
• Gastroenterology & Hepatology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Dermatology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Biodiversity & Conservation Biology (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (1)

Family

ID=84802113

Family Applications (1)

Country Status (9)

Cited By (1)

Families Citing this family (1)

Citations (2)

• 2022
  • 2022-07-08 CA CA3225064A patent/CA3225064A1/en active Pending
  • 2022-07-08 AU AU2022308056A patent/AU2022308056A1/en active Pending
  • 2022-07-08 US US18/577,545 patent/US20240327865A1/en active Pending
  • 2022-07-08 EP EP22838604.1A patent/EP4367253A4/en active Pending
  • 2022-07-08 IL IL309889A patent/IL309889A/en unknown
  • 2022-07-08 JP JP2024500069A patent/JP2024527345A/ja active Pending
  • 2022-07-08 WO PCT/US2022/073563 patent/WO2023283641A1/en not_active Ceased
  • 2022-07-08 CN CN202280059307.1A patent/CN117897494A/zh active Pending
  • 2022-07-08 KR KR1020247004164A patent/KR20240032932A/ko active Pending

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events